

**EXCELSIOR MEDICAL CO., LTD.
AND SUBSIDIARIES**

CONSOLIDATED FINANCIAL STATEMENTS

**With Independent Auditors' Report
For the Years Ended December 31, 2025 and 2024**

**Address: 17F., No.880, Zhongzheng Rd., Zhonghe Dist., New Taipei City 235,
Taiwan, R.O.C.**

Telephone: (02)22251888

The independent auditors' report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Representation Letter	3
4. Independent Auditors' Report	4
5. Consolidated Balance Sheets	5
6. Consolidated Statements of Comprehensive Income	6
7. Consolidated Statements of Changes in Equity	7
8. Consolidated Statements of Cash Flows	8
9. Notes to the Consolidated Financial Statements	
(1) Company History	9
(2) Financial Statements Authorization Date and Authorization Process	9
(3) New Standards, Amendments and Interpretations Adopted	9~11
(4) Summary of material accounting policies	11~28
(5) Significant Accounting Assumptions and Judgments, and Major Sources of Estimation Uncertainty	28
(6) Explanation of Significant Accounts	28~66
(7) Related Party Transactions	66~71
(8) Pledged Assets	71
(9) Significant Commitments and Contingencies	72
(10) Losses due to Major Disasters	72
(11) Subsequent Events	72
(12) Other	73
(13) Other disclosures	
(a) Information on significant transactions	73~75
(b) Information on investees	76~77
(c) Information on investment in mainland China	78~79
(14) Segment Information	79~80

Representation Letter

The entities that are required to be included in the combined financial statements of Excelsior Medical Co., Ltd. as of and for the year ended December 31, 2025 under the Criteria Governing the Preparation of Affiliation Reports, Consolidated Business Reports, and Consolidated Financial Statements of Affiliated Enterprises are the same as those included in the consolidated financial statements prepared in conformity with International Financial Reporting Standards No. 10, "Consolidated Financial Statements," endorsed by the Financial Supervisory Commission. In Addition, the information required to be disclosed in the combined financial statements is included in the consolidated financial statements. Consequently, Excelsior Medical Co., Ltd. and Subsidiaries do not prepare a separate set of combined financial statements.

Company name: Excelsior Medical Co., Ltd.

Chairman: Fu Hui-Tung

Date: March 6, 2026



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel + 886 2 8101 6666
傳真 Fax + 886 2 8101 6667
網址 Web kpmg.com/tw

Independent Auditors' Report

To the Board of Directors of Excelsior Medical Co., Ltd.:

Opinion

We have audited the consolidated financial statements of Excelsior Medical Co., Ltd. and its subsidiaries (“the Group”), which comprise the consolidated balance sheet as of December 31, 2025 and 2024, the consolidated statement of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, based on our audits and the reports of other auditors (please refer to Other Matter paragraph), the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and with the International Financial Reporting Standards (“IFRSs”), International Accounting Standards (“IASs”), Interpretations developed by the International Financial Reporting Interpretations Committee (“IFRIC”) or the former Standing Interpretations Committee (“SIC”) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. Based on our audits and the reports of other auditors, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Based on our judgment, the key audit matter that should be disclosed in this report is as follows:

1. Impairment Assessment on Receivables

Please refer to Note (4)(g), Note(5) and Note(6)(e) for accounting policies of account receivable allowance provision.



Description of key audit matter:

The management of the Group performed its assessment based on the default risk of accounts receivable and the rate of expected loss. Because the assessment of impairment loss of receivables involves critical accounting estimates, which are subject to the judgment of the management, the assessment of the impairment loss of receivables is deemed to be a key audit matter.

How the matter was addressed in our audit:

Our main audit procedures in response to the assessment of the impairment of receivables were assessing the reasonableness of the methodology and assumptions used by the management for the impairment assessment of receivables and whether the methodology was adopted consistently, testing the reasonableness of the information used by the management for assessing the impairment of receivables, reviewing the accuracy of the calculation of the allowance for receivables, and evaluating the adequacy of the Group's disclosure for impairment of receivables.

Other Matter

We did not audit the financial statements of certain subsidiaries included in the consolidated financial statements of the Group. Those statements were audited by other auditors, whose reports have been furnished to us, and our opinion, insofar as it relates to the amounts included for such subsidiaries, is based solely on the report of other auditors. As of December 31, 2025 and 2024, the total assets of these subsidiaries were NT\$675,901 thousand and NT\$517,772 thousand, constituting 4% and 3% of consolidated total assets, respectively. The total operating revenues of these subsidiaries for the year ended December 31, 2025 and 2024 were NT\$522,482 thousand and NT\$420,928 thousand, constituting 6% and 5% of consolidated total operating revenues, respectively. We also did not audit the financial statements of certain associates and joint ventures, which represented investment in other entities accounted for using the equity method of the Group. Those statements were audited by other auditors, whose reports have been furnished to us, and our opinion, insofar as it relates to the amounts included for such entities, is based solely on the reports of other auditors. As of December 31, 2025 and 2024, the carrying amounts of these investments were NT\$1,388,843 thousand and NT\$1,374,651 thousand, constituting 7% and 7% of consolidated total assets, respectively. The share of comprehensive income of associates and joint ventures accounted for using the equity method for the years ended December 31, 2025 and 2024, amounted to NT\$192,952 thousand and NT\$161,038 thousand, were constituting 17% and 15% of consolidated total comprehensive income, respectively.

Excelsior Medical Co., Ltd. has prepared its parent-company-only financial statements as of and for the years ended December 31, 2025 and 2024 on which we have issued an unmodified opinion with an Other Matter paragraph.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and with the IFRSs, IASs, IFRC, SIC endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.



In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including the Audit Committee) are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Kuo, Rou-Lan and Chen, Chun-Kuang.

KPMG

Taipei, Taiwan (Republic of China)
March 6, 2026

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' report and consolidated financial statements, the Chinese version shall prevail.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

ASSETS		December 31, 2025		December 31, 2024		LIABILITIES AND EQUITY		December 31, 2025		December 31, 2024	
		Amount	%	Amount	%			Amount	%	Amount	%
Current assets:						Current liabilities:					
1100	Cash and cash equivalents (Note (6)(a))	\$ 2,847,128	15	4,189,204	21	2100	Short-term borrowings (Note (6)(m))	\$ 1,343,221	7	917,531	4
1110	Current financial assets at fair value through profit or loss (Note (6)(b))	-	-	117	-	2130	Current contract liabilities	572,217	3	543,595	3
1136	Current financial assets at amortized cost (Note (6)(d))	612,160	3	757,571	4	2150	Notes payable	6,367	-	1,931	-
1151	Notes receivable (Notes (6)(e), (7) and (8))	188,111	1	219,939	1	2170	Accounts payable (Note (7))	1,139,987	6	977,039	5
1152	Other notes receivable (Notes (6)(e), (7) and (8))	213,167	1	236,916	1	2200	Other payables (Notes (6)(n) and (7))	2,596,329	14	5,307,269	26
1170	Accounts receivable (Notes (6)(e) and (7))	1,769,796	10	1,725,993	8	2230	Current tax liabilities	108,869	-	101,220	-
1200	Other receivables (Notes (6)(e) and (7))	3,036,901	16	3,424,143	17	2280	Current lease liabilities (Notes (6)(p) and (7))	140,406	1	128,343	1
130X	Inventories (Note (6)(f))	1,391,669	8	1,392,801	7	2399	Other current liabilities, others (Notes (6)(o) and (7))	284,607	1	311,733	2
1476	Other current financial assets (Note (8))	75,185	-	101,248	-			<u>6,192,003</u>	<u>32</u>	<u>8,288,661</u>	<u>41</u>
1479	Other current assets, others	232,175	1	173,008	1	Non-Current liabilities:					
		<u>10,366,292</u>	<u>55</u>	<u>12,220,940</u>	<u>60</u>	2540	Long-term borrowings (Note (6)(m))	350,000	2	-	-
Non-current assets:						2570	Deferred tax liabilities (Note (6)(s))	369,847	2	322,486	1
1517	Non-current financial assets at fair value through other comprehensive income (Note (6)(c))	881,474	5	655,910	3	2580	Non-current lease liabilities (Notes (6)(p) and (7))	320,279	2	377,827	2
1550	Investments accounted for using equity method (Note (6)(g))	4,216,105	22	4,043,825	20	2640	Net defined benefit liability (Note (6)(r))	5,020	-	4,368	-
1600	Property, plant and equipment (Notes (6)(i) and (8))	756,005	4	795,597	4	2650	Credit balance of investments accounted for using equity method (Note (6)(g))	-	-	2,675	-
1755	Right-of-use assets (Note (6)(j))	272,114	1	325,619	2	2670	Other non-current liabilities, others	15,441	-	14,631	-
1760	Investment property, net (Notes (6)(k) and (8))	1,598,242	8	1,610,545	8			<u>1,060,587</u>	<u>6</u>	<u>721,987</u>	<u>3</u>
1780	Intangible assets (Note (6)(l))	46,757	-	47,124	-	Total liabilities		<u>7,252,590</u>	<u>38</u>	<u>9,010,648</u>	<u>44</u>
1840	Deferred tax assets (Note (6)(s))	115,355	1	108,561	1	Equity attributable to owners of parent (Note (6)(t)):					
1930	Long-term notes and accounts receivable (Note (6)(e))	333,936	2	283,334	1		Share capital	1,715,674	9	1,633,975	8
1975	Net defined benefit asset (Note (6)(r))	62,527	-	53,951	-	3100	Capital surplus	3,390,833	18	3,382,788	16
1980	Other non-current financial assets (Note (8))	316,480	2	207,699	1	3200	Retained earnings	3,740,835	20	3,619,990	18
1990	Other non-current assets, others	11,910	-	14,896	-		Other equity	344,945	2	333,488	2
		<u>8,610,905</u>	<u>45</u>	<u>8,147,061</u>	<u>40</u>		Total equity attributable to owners of parent	<u>9,192,287</u>	<u>49</u>	<u>8,970,241</u>	<u>44</u>
						36XX	Non-controlling interests (Notes (6)(h) and (t))	<u>2,532,320</u>	<u>13</u>	<u>2,387,112</u>	<u>12</u>
							Total equity	<u>11,724,607</u>	<u>62</u>	<u>11,357,353</u>	<u>56</u>
TOTAL ASSETS		<u>\$ 18,977,197</u>	<u>100</u>	<u>20,368,001</u>	<u>100</u>	TOTAL LIABILITIES AND EQUITY		<u>\$ 18,977,197</u>	<u>100</u>	<u>20,368,001</u>	<u>100</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT EARNINGS PER SHARE)

		For the Years Ended December 31,			
		2025		2024	
		Amount	%	Amount	%
4000	Operating revenue (Notes (6)(v) and (7))	\$ 8,789,236	100	8,538,546	100
5000	Operating costs (Notes (6)(f) and (7))	6,914,865	79	6,757,223	79
	Gross profit from operations	1,874,371	21	1,781,323	21
5910	Less: Unrealized profit from sales	90,424	1	90,924	1
5920	Add: Realized profit from sales	88,687	1	95,065	1
		<u>1,872,634</u>	<u>21</u>	<u>1,785,464</u>	<u>21</u>
	Operating expenses:				
6100	Selling expenses (Note (7))	762,001	9	660,339	8
6200	Administrative expenses (Note (7))	386,956	4	371,317	4
6450	Expected credit loss (gain) (Note (6)(e))	(3,862)	-	492	-
		<u>1,145,095</u>	<u>13</u>	<u>1,032,148</u>	<u>12</u>
	Net operating income	<u>727,539</u>	<u>8</u>	<u>753,316</u>	<u>9</u>
	Non-operating income and expenses:				
7100	Interest income (Note (6)(x))	75,581	1	76,736	1
7010	Other income (Notes (6)(x) and (7))	13,481	-	22,346	-
7020	Other gains and losses (Notes (6)(x) and (7))	(1,193)	-	25,887	-
7050	Finance costs (Notes (6)(x) and (7))	(34,918)	-	(27,116)	-
7060	Share of profit of associates and joint ventures accounted for using equity method (Note (6)(g))	401,417	4	323,193	3
		<u>454,368</u>	<u>5</u>	<u>421,046</u>	<u>4</u>
7900	Profit before tax	<u>1,181,907</u>	<u>13</u>	<u>1,174,362</u>	<u>13</u>
7950	Less: Tax expense (Note (6)(s))	<u>216,300</u>	<u>2</u>	<u>203,307</u>	<u>2</u>
	Profit	<u>965,607</u>	<u>11</u>	<u>971,055</u>	<u>11</u>
	Other comprehensive income (loss):				
8310	Items that may not be reclassified subsequently to profit or loss:				
8311	Gains on remeasurements of defined benefit plans	6,053	-	28,975	-
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	273,731	3	(74,901)	(1)
8320	Share of other comprehensive income of associates and joint ventures accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss	(18,555)	-	11,461	-
8349	Less: Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	55,614	1	69,578	-
	Total items that will not be reclassified subsequently to profit and loss	<u>205,615</u>	<u>2</u>	<u>(104,043)</u>	<u>(1)</u>
8360	Items that will be reclassified to profit or loss				
8361	Exchange differences on translation	(117,968)	(1)	296,219	3
8370	Share of other comprehensive income of associates and joint ventures accounted for using equity method, components of other comprehensive income that will be reclassified to profit or loss	51,748	-	(72,209)	(1)
8399	Less: Income tax related to components of other comprehensive income that will be reclassified to profit or loss	(8,671)	-	30,695	-
	Total items that will be reclassified subsequently to profit and loss	<u>(57,549)</u>	<u>(1)</u>	<u>193,315</u>	<u>2</u>
	Other comprehensive income, net	<u>148,066</u>	<u>1</u>	<u>89,272</u>	<u>1</u>
8500	Total comprehensive income	<u>\$ 1,113,673</u>	<u>12</u>	<u>1,060,327</u>	<u>12</u>
	Profit attributable to:				
8610	Owners of parent	\$ 805,860	9	771,259	9
8620	Non-controlling interests	159,747	2	199,796	2
		<u>\$ 965,607</u>	<u>11</u>	<u>971,055</u>	<u>11</u>
	Comprehensive income attributable to:				
8710	Owners of parent	\$ 834,884	9	854,869	10
8720	Non-controlling interests	278,789	3	205,458	2
		<u>\$ 1,113,673</u>	<u>12</u>	<u>1,060,327</u>	<u>12</u>
	Earnings per share (Note (6)(u))				
9750	Basic earnings per share (NT dollars)	<u>\$ 4.70</u>		<u>4.50</u>	
9850	Diluted earnings per share (NT dollars)	<u>\$ 4.68</u>		<u>4.48</u>	

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Equity attributable to owners of parent					Total other equity interest				Total equity
	Share capital	Retained earnings				Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Equity attributable to owners of parent	Non-controlling interests	
	Ordinary shares	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings					
Balance as of January 1, 2024	\$ 1,556,167	3,287,576	974,960	-	2,527,642	(122,201)	388,865	8,613,009	2,299,950	10,912,959
Profit for the year	-	-	-	-	771,259	-	-	771,259	199,796	971,055
Other comprehensive income (loss) for the year	-	-	-	-	16,786	111,472	(44,648)	83,610	5,662	89,272
Total comprehensive income (loss) for the year	-	-	-	-	788,045	111,472	(44,648)	854,869	205,458	1,060,327
Appropriation and distribution of retained earnings:										
Legal reserve appropriated	-	-	77,322	-	(77,322)	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(591,344)	-	-	(591,344)	-	(591,344)
Stock dividends of ordinary share	77,808	-	-	-	(77,808)	-	-	-	-	-
Changes in ownership interests in subsidiaries	-	94,873	-	-	(1,505)	-	-	93,368	64,213	157,581
Difference between consideration and carry amounts of the subsidiaries acquired or disposed	-	339	-	-	-	-	-	339	-	339
Changes in non-controlling interests	-	-	-	-	-	-	-	-	(182,509)	(182,509)
Balance as of December 31, 2024	1,633,975	3,382,788	1,052,282	-	2,567,708	(10,729)	344,217	8,970,241	2,387,112	11,357,353
Profit for the year	-	-	-	-	805,860	-	-	805,860	159,747	965,607
Other comprehensive income (loss) for the year	-	-	-	-	6,501	(32,938)	55,461	29,024	119,042	148,066
Total comprehensive income (loss) for the year	-	-	-	-	812,361	(32,938)	55,461	834,884	278,789	1,113,673
Appropriation and distribution of retained earnings:										
Legal reserve appropriated	-	-	78,654	-	(78,654)	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(620,910)	-	-	(620,910)	-	(620,910)
Stock dividends of ordinary share	81,699	-	-	-	(81,699)	-	-	-	-	-
Changes in equity of associates and joint ventures accounted for using equity method	-	7,976	-	-	(686)	-	(40)	7,250	-	7,250
Changes in ownership interests in subsidiaries	-	-	-	-	11,026	-	(11,026)	-	-	-
Changes in non-controlling interests	-	69	-	-	753	-	-	822	(133,581)	(132,759)
Balance at December 31, 2025	<u>\$ 1,715,674</u>	<u>3,390,833</u>	<u>1,130,936</u>	<u>-</u>	<u>2,609,899</u>	<u>(43,667)</u>	<u>388,612</u>	<u>9,192,287</u>	<u>2,532,320</u>	<u>11,724,607</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	For the Years Ended December 31,	
	2025	2024
Cash flows from operating activities:		
Profit before tax	\$ 1,181,907	1,174,362
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expense	306,050	294,976
Amortization expense	7,633	5,856
Expected credit (gain) loss	(3,862)	492
Net loss on financial assets or liabilities at fair value through profit or loss	1,865	(1,855)
Interest expense	34,918	27,116
Interest income	(75,581)	(76,736)
Dividend income	(9,371)	(16,821)
Share of profit of associates and joint ventures accounted for using equity method	(401,417)	(323,193)
Gain on disposal of property, plan and equipment	-	(764)
Unrealized profit from sales	90,424	90,924
Realized profit from sales	(88,687)	(95,065)
Profit from lease modification	(36)	(4,121)
Total adjustments to reconcile profit	(138,064)	(99,191)
Changes in operating assets and liabilities:		
Changes in operating assets:		
Notes receivable	29,706	85,132
Accounts receivable	4,631	(67,750)
Other receivables and notes	407,845	199,157
Inventories	(88,467)	(264,071)
Net defined benefit asset	(8,576)	(24,618)
Other current assets	(90,181)	(40,766)
Total changes in operating assets	254,958	(112,916)
Changes in operating liabilities:		
Contract liabilities	28,622	(15,571)
Notes payable	4,436	134
Accounts payable	162,948	4,110
Other payables	(2,711,336)	1,661,961
Other current liabilities	(27,126)	(20,023)
Net defined benefit liability	8,359	25,843
Other operating liabilities	2,445	821
Total changes in operating liabilities	(2,531,652)	1,657,275
Total changes in operating assets and liabilities	(2,276,694)	1,544,359
Total adjustments	(2,414,758)	1,445,168
Cash (outflow) inflow generated from operations	(1,232,851)	2,619,530
Interest received	73,798	80,346
Income taxes paid	(204,577)	(228,431)
Net cash flows (used in) from operating activities	(1,363,630)	2,471,445

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	For the Years Ended December 31,	
	2025	2024
Cash flows from (used in) investing activities:		
Acquisition of financial assets at fair value through other comprehensive income	(855)	(2,387)
Proceeds from disposal of financial assets at fair value through other comprehensive income	48,930	-
Acquisition of financial assets at amortized cost	(513,467)	(592,789)
Proceeds from disposal of financial assets at amortized cost	655,353	612,075
Acquisition of financial assets at fair value through profit or loss	(3,421)	1,738
Proceeds from disposal of financial assets at fair value through profit or loss	1,673	-
Acquisition of investments accounted for using equity method	(8,000)	-
Proceeds from disposal of investments accounted for using equity method	-	11,701
Acquisition of property, plant and equipment	(77,787)	(114,866)
Proceeds from disposal of property, plant and equipment	-	1,027
Increase in refundable deposits	(109,747)	11,807
Acquisition of intangible assets	(5,251)	(5,828)
Acquisition of investment properties	-	(249,160)
Other financial assets	27,029	(76,734)
Other non-current assets	1,322	12,140
Dividends received	209,113	325,709
Net cash flows from (used in) investing activities	224,892	(65,567)
Cash flows from (used in) financing activities:		
Increase (decrease) in short-term borrowings	425,690	(217,356)
Proceeds from long-term borrowings	350,000	-
(Decrease) increase in guarantee deposits received	(1,635)	6,963
Payment of lease liabilities	(137,284)	(101,269)
Cash dividends paid	(620,910)	(591,344)
Disposal of ownership interests in subsidiaries (without losing control)	-	159,086
Interest paid	(31,334)	(29,527)
Change in non-controlling interests	(133,511)	(182,509)
Net cash flows used in financing activities	(148,984)	(955,956)
Effect of exchange rate changes on cash and cash equivalents	(54,354)	124,496
Net (decrease) increase in cash and cash equivalents	(1,342,076)	1,574,418
Cash and cash equivalents at beginning of period	4,189,204	2,614,786
Cash and cash equivalents at end of period	\$ 2,847,128	4,189,204

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(1) Company History

Excelsior Medical Co., Ltd. (the Company) was incorporated on March 15, 1988 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is 17F., No.880, Zhongzheng Rd., Zhonghe Dist., New Taipei City 235, Taiwan, R.O.C.. The Company and its subsidiaries (the Group) engaged primarily in the sale of medical supplies and equipment, medicines and home medical devices.

The Company's shares were traded on the Taipei Exchange (formerly the GreTai Securities Market) from June 8, 2001 to December 31, 2007 and have been traded on the Taiwan Stock Exchange since December 31, 2007.

(2) Financial Statements Authorization Date and Authorization Process

These consolidated financial statements were authorized for issue by the Board of Directors on March 6, 2026.

(3) New Standards, Amendments and Interpretations Adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2025:

- Amendments to IAS21 “Lack of Exchangeability”

- (b) The impact of IFRS Accounting Standards endorsed by the FSC but not yet effective

The Group assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2026, would not have a significant impact on its consolidated financial statements:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

- (c) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none">• A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities.• Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards.• Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.	January 1, 2027 note: On September 25, 2025, the FSC issued a press release announcing that Taiwan will adopt IFRS 18 beginning in 2028. Entities that need to adopt the new standard earlier may do with the endorsement of the FSC.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures” and amendments to IFRS 19 “Subsidiaries without Public Accountability: Disclosures”
- Amendments to IAS 21 “Translation to a Hyperinflationary Presentation Currency”

(4) Summary of material accounting policies

The significant accounting policies presented in the consolidated financial statements are summarized below. The following accounting policies were applied consistently throughout the periods presented in the consolidated financial statements.

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to "the Regulations") and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the Financial Supervisory Commission, R.O.C. (hereinafter referred to the "IFRS Accounting Standard" endorsed by "FSC").

(b) Basis of preparation

1. Basis of measurement

The consolidated financial statements have been prepared on historical cost basis except for the following material items in the balance sheet:

- 1) Financial assets at fair value through profit or loss are measured at fair value;
- 2) Financial assets at fair value through other comprehensive income are measured at fair value;
- 3) The defined benefit liabilities (or assets) are measured at fair value of plan assets, net of aggregation of the present value of the defined benefit obligation, with a limit based on a defined benefit asset.

2. Functional and presentation currency

The functional currency of each Group entity is determined based on the primary economic environment in which the entity operates. The consolidated financial statements are presented in New Taiwan Dollars, which is the Company's functional currency. All financial information presented in New Taiwan Dollars has been rounded to the nearest thousand.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(c) Basis of consolidation

1. Principle of preparation of the consolidated financial statements

The consolidated financial statements comprise the Company and subsidiaries. Subsidiaries are entities controlled by the Group. The Group ‘controls’ an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.

The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Intragroup balances and transactions, and any unrealized income and expenses arising from Intragroup transactions are eliminated in preparing the consolidated financial statements. The Group attributes the profit or loss and each component of other comprehensive income to the owners of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance.

The Group prepares consolidated financial statements using uniform accounting policies for like transactions and other events in similar circumstances. Changes in the Group’s ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received will be recognized directly in equity, and the Group will attribute it to the owners of the parent.

2. List of subsidiaries in the consolidated financial statements :

Name of Investor	Name of Subsidiary	Principal Activity	Shareholding		Note
			December 31, 2025	December 31, 2024	
The Company	Dynamic Medical Technologies Inc. (“Dynamic”)	Sale, maintenance and lease of laser medical equipment for beauty treatment, and sale of consumables of beauty treatment and cosmetic products	33.97 %	33.96 %	Note 1、2
”	Excelsior Healthcare Co., Limited (Excelsior Healthcare)	Investment business	100.00 %	100.00 %	
”	Arich Enterprise Co., Ltd. (Arich)	Sale of medicines, and logistics service	40.00 %	40.00 %	Note 1
”	Excelsior Asset Management Co., Ltd. (“Excelsior Asset”)	Sales of medical equipment, precision instrument and real estate	100.00 %	100.00 %	
The Company and Excelsior Healthcare	Excelsior Medical (HK) Co., Limited (“Hong Kong Excelsior”)	Investment business	100.00 %	100.00 %	
Dynamic	Dynamic Medical Technologies (Hong Kong) Ltd. (“Hong Kong Dynamic”)	Sale of cosmetic health care products	100.00 %	100.00 %	
”	CYJ International Taiwan Inc. (CYJ Taiwan)	Sales of lifestyle beauty products and treatments, and sales of medical beauty products.	55.41 %	55.41 %	Note 3
The Company and Dynamic	Excelsior Beauty Co., Ltd. (“Excelsior Beauty”)	Sales of lifestyle beauty products and treatments, and sales of medical beauty products.	94.91 %	94.91 %	
Hong Kong Dynamic	Guangzhou Dynamic Inc. (“Guangzhou Dynamic”)	Sale and maintenance of medical equipment	100.00 %	100.00 %	
Arich Enterprise Co., Ltd.	Arich Best Chain Co., Ltd. (Arich Best Chain)	Logistics business	100.00 %	100.00 %	
Excelsior Healthcare	EG Healthcare, Inc.	Sale and lease of medical equipment, and medical management consultancy service	99.99 %	99.99 %	
”	Excelsior Investment (Malaysia) Co., Ltd	Investment business	100.00 %	100.00 %	

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of Investor	Name of Subsidiary	Principal Activity	Shareholding		Note
			December 31, 2025	December 31, 2024	
Hong Kong Excelsior	SinoExcelsior Investment Inc. ("SinoExcelsior Investment")	Sale of medical equipment, and medical management consultancy service	100.00 %	100.00 %	
Excelsior Investment (Malaysia) Co., Ltd.	Renal Laboratories Sdn. Bhd.	Manufacture of medical equipment	81.90 %	81.90 %	
"	Medi-Chem Systems Sdn. Bhd.	Sale of medical equipment	70.00 %	70.00 %	
Medi-Chem Systems Sdn. Bhd.	Renal Management Sdn. Bhd.	Lease business	100.00 %	100.00 %	

Note 1: Although the Company holds less than 50% of the shares of Dynamic and Arich, these companies' other equity shares are highly separated. Therefore, the Company still maintains control over Dynamic and Arich, and these companies are included in the consolidated financial statements.

Note 2: The Company bought the fractional shares of Dynamic in September 2025 acquiring 0.004%, of Dynamic's shares, while still maintaining control over Dynamic.

Note 3: CYJ International Taiwan Inc. conducted a cash capital increase by issuing 12,759,960 new shares, amount to NT\$127,600 thousand, with the base date set on July 1, 2024, based on a resolution approved during its board meeting held on April 24, 2024, in which the Company subscribed 6,507,580 shares, at the amount of NT\$65,076 thousand, resulting in the Company's shareholding ratio to decrease to 55.41%.

3.Subsidiaries excluded from the consolidated financial statements: None.

(d) Foreign Currencies

1.Foreign currency transactions

Transactions in foreign currencies are translated into the respective functional currencies of Group entities at the exchange rates at the dates of the transactions. At the end of each subsequent reporting period, monetary items denominated in foreign currencies are translated into the functional currencies using the exchange rate at that date. Non-monetary items denominated in foreign currencies that are measured at fair value are translated into the functional currencies using the exchange rate at the date that the fair value was determined. Non-monetary items denominated in foreign currencies that are measured based on historical cost are translated using the exchange rate at the date of the transaction.

Exchange differences are generally recognized in profit or loss, except for those differences relating to the following, which are recognized in other comprehensive income:

- 1) an investment in equity securities designated as at fair value through other comprehensive income;
- 2) a financial liability designated as a hedge of the net investment in a foreign operation to the extent that the hedge is effective; or
- 3) qualifying cash flow hedges to the extent that the hedges are effective.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2. Foreign operations

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into the presentation currency at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into the presentation currency at the average exchange rate. Exchange differences are recognized in other comprehensive income.

When a foreign operation is disposed of such that control, significant influence, or joint control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. When the Group disposes of only part of its interest in a subsidiary that includes a foreign operation while retaining control, the relevant proportion of the cumulative amount is reattributed to non controlling interests. When the Group disposes of only part of its investment in an associate or joint venture that includes a foreign operation while retaining significant influence or joint control, the relevant proportion of the cumulative amount is reclassified to profit or loss.

When the settlement of a monetary receivable from or payable to a foreign operation is neither planned nor likely to occur in the foreseeable future, exchange differences arising from such a monetary item that are considered to form part of the net investment in the foreign operation are recognized in other comprehensive income.

(e) Classification of Current and Non-Current Assets and Liabilities

The Group classifies the asset as current under one of the following criteria, and all other assets are classified as non-current.

1. It is expected to be realized, or intended to be sold or consumed, in the normal operating cycle;
2. It is held primarily for the purpose of trading;
3. It is expected to be realized within twelve months after the reporting period; or
4. The asset is cash or a cash equivalent (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Group classifies the liability as current under one of the following criteria, and all other liabilities are classified as non-current.

1. It is expected to be settled in the normal operating cycle;
2. It is held primarily for the purpose of trading;
3. It is due to be settled within twelve months after the reporting period; or
4. The Group does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(f) Cash and Cash Equivalents

Cash comprises cash on hand and demand deposits. Cash equivalents are short term, highly liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value. Time deposits which meet the above definition and are held for the purpose of meeting short term cash commitments rather than for investment or other purposes should be recognized as cash equivalents.

Bank overdrafts that are repayable on demand and form an integral part of the Group's cash management are included as a component of cash and cash equivalents for the purpose of the consolidated statement of cash flows.

(g) Financial instruments

Trade receivables and debt securities issued are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when the Group becomes a party to the contractual provisions of the instrument. A financial asset (unless it is a trade receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

1. Financial assets

All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis.

On initial recognition, a financial asset is classified as measured at: amortized cost; Fair value through other comprehensive income (FVOCI) – equity investment; or FVTPL. Financial assets are not reclassified subsequent to their initial recognition unless the Group changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

1) Financial assets measured at amortized cost

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

These assets are subsequently measured at amortized cost, which is the amount at which the financial asset is measured at initial recognition, plus/minus, the cumulative amortization using the effective interest method, adjusted for any loss allowance. Interest income, foreign exchange gains and losses, as well as impairment, are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Fair value through other comprehensive income (FVOCI)

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Some trade receivables are held within a business model whose objective is achieved by both collecting contractual cash flows and selling by the Group; therefore, those receivables are measured at FVOCI. However, they are included in the ‘trade receivables’ line item.

On initial recognition of an equity investment that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment’s fair value in other comprehensive income. This election is made on an instrument-by-instrument basis.

Equity investments at FVOCI are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in other comprehensive income and are never reclassified to profit or loss.

Dividend income is recognized in profit or loss on the date on which the Group’s right to receive payment is established.

3) Fair value through profit or loss (FVTPL)

All financial assets not classified as amortized cost or FVOCI described as above are measured at FVTPL, including derivative financial assets. Trade receivables that the Group intends to sell immediately or in the near term are measured at FVTPL; however, they are included in the ‘trade receivables’ line item. On initial recognition, the Group may irrevocably designate a financial asset, which meets the requirements to be measured at amortized cost or at FVOCI, as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

4) Impairment of financial assets

The Group recognizes loss allowances for expected credit losses (ECL) on financial assets measured at amortized cost (including cash and cash equivalents, amortized costs, notes and trade receivables, other receivable, leases receivable, guarantee deposit paid and other financial assets).

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group measures loss allowances at an amount equal to lifetime ECL, except for the following which are measured as 12-month ECL:

- debt securities that are determined to have low credit risk at the reporting date; and
- other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowance for trade receivables are always measured at an amount equal to lifetime ECL.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECL, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis based on the Group's historical experience and informed credit assessment as well as forward-looking information.

Lifetime ECL are the ECL that result from all possible default events over the expected life of a financial instrument.

12-month ECL are the portion of ECL that result from default events that are possible within the 12 month after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

The maximum period considered when estimating ECL is the maximum contractual period over which the Group is exposed to credit risk.

ECL are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e the difference between the cash flows due to the Group in accordance with the contract and the cash flows that the Group expects to receive). ECL are discounted at the effective interest rate of the financial asset.

At each reporting date, the Group assesses whether financial assets carried at amortized cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. Evidence that a financial assets is credit-impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- a breach of contract such as a default or being past due;
- the lender of the borrower, for economic or contractual reasons relating to the borrower's financial difficulty, having granted to the borrower a concession that the lender would not otherwise consider;
- it is probable that the borrower will enter bankruptcy or other financial reorganization; or
- the disappearance of an active market for a security because of financial difficulties.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is charge to profit or loss and is recognized in other comprehensive income instead of reducing the carrying amount of the asset.

The gross carrying amount of a financial asset is written off when the Group has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. For corporate customers, the Group individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery. The Group expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Group's procedures for recovery of amounts due.

5) Derecognition of financial assets

The Group derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset.

The Group enters into transactions whereby it transfers assets recognized in its statement of balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets. In these cases, the transferred assets are not derecognized.

2. Financial liabilities and equity instruments

1) Classification of debt or equity

Debt and equity instruments issued by the Group are classified as financial liabilities or equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

2) Equity instrument

An equity instrument is any contract that evidences residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued are recognized as the amount of consideration received, less the direct cost of issuing.

3) Financial liabilities

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss.

Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4) Derecognition of financial liabilities

The Group derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. The Group also derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.

On derecognition of a financial liability, the difference between the carrying amount of a financial liability extinguished and the consideration paid (including any non-cash assets transferred or liabilities assumed) is recognized in profit or loss.

5) Offsetting of financial assets and liabilities

Financial assets and financial liabilities are offset and the net amount presented in the statement of balance sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

3. Derivative financial instruments

The Group holds derivative financial instruments to hedge its foreign currency and interest rate exposures. Embedded derivatives are separated from the host contract and accounted for separately if the host contract is not a financial asset and certain criteria are met.

Derivatives are initially measured at fair value. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are generally recognized in profit or loss.

(h) Inventories

Inventories are measured at the lower of cost and net realizable value. The cost of inventories is calculated using the weighted average method, and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their present location and condition.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

(i) Investment in Associates

Associates are those entities in which the Group has significant influence, but not control or joint control, over their financial and operating policies.

Investments in associates are accounted for using the equity method and are recognized initially at cost. The cost of the investment includes transaction costs. The carrying amount of the investment in associates includes goodwill arising from the acquisition less any accumulated impairment losses.

The consolidated financial statements include the Group's share of the profit or loss and other comprehensive income of those associates, after adjustments to align their accounting policies with those of the Group, from the date on which significant influence commences until the date on which significant influence ceases. The Group recognizes any changes of its proportionate share in the investee within capital surplus, when an associate's equity changes due to reasons other than profit and loss or comprehensive income, which did not result in changes in actual proportionate share.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Gains and losses resulting from transactions between the Group and an associate are recognized only to the extent of unrelated Group's interests in the associate.

When the Group's share of losses of an associate equals or exceeds its interests in an associate, it discontinues recognizing its share of further losses. After the recognized interest is reduced to zero, additional losses are provided for, and a liability is recognized, only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate.

When the Group subscribes to additional shares in an associate at a percentage different from its existing ownership percentage, the resulting carrying amount of the investment will differ from the amount of the Group's proportionate interest in the net assets of the associate. The Group records such a difference as an adjustment to investments, with the corresponding amount charged or credited to capital surplus. The aforesaid adjustment should first be adjusted under capital surplus. If the capital surplus resulting from changes in ownership interest is not sufficient, the remaining difference is debited to retained earnings. If the Group's ownership interest is reduced due to the additional subscription to the shares of the associate by other investors, the proportionate amount of the gains or losses previously recognized in other comprehensive income in relation to that associate will be reclassified to profit or loss on the same basis as would be required if the associate had directly disposed of the related assets or liabilities.

(j) Investment Property

Investment property is property held either to earn rental income or for capital appreciation or for both, but not for sale in the ordinary course of business, use in the production or supply of goods or services, or for administrative purposes. Investment property is measured at cost on initial recognition, and subsequently at cost, less accumulated depreciation and accumulated impairment losses. Depreciation expense is calculated based on the depreciation method, useful life, and residual value which are the same as those adopted for property, plant and equipment.

Any gain or loss on disposal of an investment property (calculated as the difference between the net proceeds from disposal and the carrying amount) is recognized in profit or loss.

Rental income from investment property is recognized as other revenue on a straight-line basis over the term of the lease. Lease incentives granted are recognized as an integral part of the total rental income, over the term of the lease.

(k) Property, Plant, and Equipment

1. Recognition and measurement

Items of property, plant and equipment are measured at cost (including capitalization of borrowing cost) less accumulated depreciation and any accumulated impairment losses.

If significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2.Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

3.Depreciation

Depreciation is calculated on the cost of an asset less its residual value and is recognized in profit or loss on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment.

Land is not depreciated.

The estimated useful lives of property, plant and equipment for current and comparative periods are as follows:

1) Buildings	5 years~ 55 years
2) Medical equipment	2 years~ 8 years
3) Other equipment	2 years~ 10 years
4) Leasehold improvements	2 years~ 10 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

(l) Leases

At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

1. As a lessee

The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be reliably determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Lease payments included in the measurement of the lease liability comprise the following:

- fixed payments, including in-substance fixed payments;
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when:

- there is a change in future lease payments arising from the change in an index or rate; or
- there is a change in the Group's estimate of the amount expected to be payable under a residual value guarantee; or
- there is a change in the lease term resulting from a change of its assessment on whether it will exercise an option to purchase the underlying asset, or
- there is a change of its assessment on whether it will exercise a extension or termination option; or
- there is any lease modifications

When the lease liability is remeasured, other than lease modifications, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or in profit and loss if the carrying amount of the right-of-use asset has been reduced to zero.

When the lease liability is remeasured to reflect the partial or full termination of the lease for lease modifications that decrease the scope of the lease, the Group accounts for the remeasurement of the lease liability by decreasing the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognize in profit or loss any gain or loss relating to the partial or full termination of the lease.

The Group presents right-of-use assets that do not meet the definition of investment and lease liabilities as a separate line item respectively in the statement of financial position.

The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases of storage room, machinery and parking space that have a lease of low-value assets. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

2. As a lessor

When the Group acts as a lessor, it determines at lease commencement whether each lease is a finance lease or an operating lease. To classify each lease, the Group makes an overall assessment of whether the lease transfers to the lessee substantially all of the risks and rewards of ownership incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then the lease is an operating lease. As part of this assessment, the Group considers certain indicators such as whether the lease is for the major part of the economic life of the asset.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

When the Group is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease. If a head lease is a short-term lease to which the Group applies the exemption described above, then it classifies the sub-lease as an operating lease.

If an arrangement contains lease and non-lease components, the Group applies IFRS15 to allocate the consideration in the contract.

The Group recognizes lease payments received under operating lease as income on a straight-line basis over the lease term as part of 'other income'.

The Group recognizes a finance lease receivable at an amount equal to its net investment in the lease. Initial direct costs, such as lessors to negotiate and arrange a lease, are included in the measurement of the net investment. The interest income is recognized over the lease term based on a pattern reflecting a constant periodic rate of return on the net investment in the lease. The Group recognizes lease payments received under operating leases as income on a straight-line basis over the lease term as part of 'other income'.

(m) Intangible Assets

1. Recognition and measurement

Goodwill arising on the acquisition of subsidiaries is measured at cost, less accumulated impairment losses.

Other intangible assets that are acquired by the Group and have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

2. Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

3. Amortization

Amortization is calculated over the cost of the asset, less its residual value, and is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use.

The estimated useful lives for current and comparative periods are as follows:

- | | |
|----------------------------|------------------|
| 1) Computer software | 1 years~ 3 years |
| 2) Other intangible assets | 2 years~ 5 years |

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(n) Impairment of Non-Financial Assets

At each reporting date, the Group reviews the carrying amounts of its non-financial assets (other than inventories and deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. Goodwill is tested annually for impairment.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill arising from a business combination is allocated to CGUs or groups of CGUs that are expected to benefit from the synergies of the combination.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount.

Impairment losses are recognized in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets in the CGU on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. For other assets, an impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

(o) Provisions

A provision is recognized if, as a result of a past event, the Group has a present obligation that can be estimated reliably, and it is probably that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects the current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost.

(p) Revenue

1. Revenue from contracts with customers

Revenue is measured based on the consideration to which the Group expects to be entitled in exchange for transferring goods or services to a customer. The Group recognizes revenue when it satisfies a performance obligation by transferring control of a good or a service to a customer. The accounting policies for the Group's main types of revenue are explained below.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

1) Sale of goods

The Group recognizes revenue when control of the products has transferred, being when the products are delivered to the customer, the customer has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, the acceptance provisions have lapsed, or the Group has objective evidence that all criteria for acceptance have been satisfied.

The Group's obligation for the sales of goods components under the standard warranty terms is recognized as a provision for warranty.

A receivable is recognized when the goods are delivered as this is the point in time that the Group has a right to an amount of consideration that is unconditional.

2) Services

The Group provides maintenance and warranty services. Revenue from providing services is recognized in the accounting period in which the services are rendered. Under the IFRS 15, the total consideration in the service contracts will be allocated to all services based on their stand-alone selling prices. The stand-alone selling prices will be determined based on the list prices at which the Group sells the services in separate transactions.

Estimates of revenues, costs or extent of progress toward completion are revised if circumstances change. Any resulting increases or decreases in estimated revenues or costs are reflected in profit or loss in the period in which the circumstances that give rise to the revision become known by management.

In case of fixed-price contracts, the customer pays the fixed amount based on a payment schedule. If the services rendered by the Group exceed the payment, a contract asset is recognized. If the payments exceed the services rendered, a contract liability is recognized.

3) Financing components

The Group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.

(q) Income Taxes

Income taxes comprise current taxes and deferred taxes. Except for expenses related to business combinations or recognized directly in equity or other comprehensive income, all current and deferred taxes are recognized in profit or loss.

The Group has determined that interest and penalties related to income taxes, including uncertain tax treatment, do not meet the definition of income taxes, and therefore accounted for them under IAS37.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Current taxes comprise the expected tax payables or receivables on the taxable profits (losses) for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax payables or receivables are the best estimate of the tax amount expected to be paid or received. It is measured using tax rates enacted or substantively enacted at the reporting date.

Deferred taxes arise due to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases. Deferred taxes are recognized except for the following:

1. temporary differences on the initial recognition of assets and liabilities in a transaction that is not a business combination and at the time of the transaction (i) affects neither accounting nor taxable profits (losses) and (ii) does not give rise to equal taxable and deductible temporary differences.
2. temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and
3. taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets are recognized for the carry forward of unused tax losses, unused tax credits, and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefits will be realized; such reductions are reversed when the probability of future taxable profits improves.

Deferred taxes are measured at tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date.

Deferred tax assets and liabilities are offset if the following criteria are met:

1. the Group has a legally enforceable right to set off current tax assets against current tax liabilities; and
2. the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on either:
 - 1) the same taxable entity; or
 - 2) different taxable entities which intend to settle current tax assets and liabilities on a net basis, or to realize the assets and liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

(r) Employee Benefits

1. Defined contribution plans

Obligations for contributions to defined contribution plans are expensed as the related service is provided.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2. Defined benefit plans

The Group's net obligation in respect of defined benefit plans is calculated separately for each the plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The calculation of defined benefit obligations is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Group, the recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in other comprehensive income, and accumulated in retained earnings. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset). Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in profit or loss. The Group recognizes gains and losses on the settlement of a defined benefit plan when the settlement occurs.

3. Other long-term employee benefits

The Group's net obligation in respect of long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods. That benefit is discounted to determine its present value. Remeasurements are recognized in profit or loss in the period in which they arise.

4. Termination benefits

Termination benefits are expensed at the earlier of when the Group can no longer withdraw the offer of those benefits and when the Group recognizes costs for a restructuring. If benefits are not expected to be settled wholly within 12 months of the reporting date, then they are discounted.

5. Short-term employee benefits

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(s) Earnings per Share

The Group discloses the Company's basic and diluted earnings per share attributable to ordinary shareholders of the Company. Basic earnings per share is calculated as the profit attributable to ordinary shareholders of the Company divided by the weighted average number of ordinary shares outstanding. Diluted earnings per share is calculated as the profit attributable to ordinary shareholders of the Company divided by the weighted average number of ordinary shares outstanding after adjustment for the effects of all potentially dilutive ordinary shares.

(t) Operating Segments

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the Group). Operating results of the operating segment are regularly reviewed by the Group's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. Each operating segment consists of standalone financial information.

(5) Significant Accounting Assumptions and Judgments, and Major Sources of Estimation Uncertainty

In preparing these consolidated financial statements, management has made judgments and estimates about the future, including climate-related risks and opportunities, that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis and are consistent with the Group's risk management and climate-related commitments where appropriate. Revisions to estimates are recognized prospectively in the period of the change and future periods.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year is as follows:

The loss allowance of trade receivable

The Group has estimated the loss allowance of trade receivable that is based on the risk of a default occurring and the rate of expected credit loss. The Group has considered historical experience, current economic conditions and forward-looking information at the reporting date to determine the assumptions to be used in calculating the impairments and the selected inputs. The relevant assumptions and input values, please refer to Note (6)(d).

(6) Explanation of Significant Accounts

(a) Cash and cash equivalents

	December 31, 2025	December 31, 2024
Cash on hand, demand deposits and checking accounts	\$ 2,180,593	2,210,164
Time deposits	666,535	1,979,040
Cash and cash equivalents in consolidated statement of cash flows	\$ 2,847,128	4,189,204

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group interest risk and sensibility analysis of the financial assets and liabilities was disclosed in Note (6)(y).

(b) Financial assets or financial liabilities at fair value through profit or loss

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Mandatorily measured at fair value through profit or loss:		
Forward foreign exchange contracts	\$ <u> -</u>	<u> 117</u>
Held-for-trading financial liabilities		

The Group holds derivative financial instruments to hedge certain foreign exchange and interest rate risk exposures arising from its operating, financing and investing activities. The following derivative instruments, without the application of hedge accounting, were classified as mandatorily measured at fair value through profit or loss and held-for-trading financial liabilities:

Forward foreign exchange contracts:

	<u>December 31, 2024</u>		
	<u>Amount</u> <u>(in thousands)</u>	<u>Currency</u>	<u>Maturity period</u>
Forward foreign exchange contracts purchased	JPY 103,867	JPY to TWD	2025.1

(c) Financial assets at fair value through other comprehensive income

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Equity investments at fair value through other comprehensive income		
Domestic listed shares	\$ 2,659	2,391
Foreign listed shares	248,855	121,050
Domestic unlisted shares	132,312	151,165
Foreign unlisted shares	<u>497,648</u>	<u>381,304</u>
Total	<u>\$ 881,474</u>	<u> 655,910</u>

1. Equity investments at fair value through other comprehensive income

The Group designated the investments shown above as equity securities at fair value through other comprehensive income because these equity securities represent those investments that the Group intends to hold for long term for strategic purposes.

The Group has sold its common stocks designated at fair value through other comprehensive income because of operation strategies for the year ended December 31, 2025. The shares sold had a fair value of \$48,930 thousand. The Group realized a gain of \$32,460 thousand, which was included in other comprehensive income (equity attributable to owners of parent), and thereafter, was transferred to retained earnings from other equity.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

There were no disposals of strategic investments and transfers of any cumulative gain or loss within equity relating to these investments for the year ended 2024.

2. For credit risk and market risk, please refer to Note (6)(y).

3. As of December 31, 2025 and 2024, the aforesaid financial assets were not pledged as collateral.

(d) Financial assets measured at amortized cost

	December 31, 2025	December 31, 2024
Time deposits with original maturity of more than 3 months	<u>\$ 612,160</u>	<u>757,571</u>

The Group has assessed that these financial assets are held to maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments have been classified as financial assets measured at amortized cost.

The market interest rates of the time deposits with original maturity of more than 3 months were 1.100%~1.70% and 1.255%~4.60% as of December 31, 2025 and 2024, respectively.

(e) Notes receivable, accounts receivable, lease payment receivable and other receivables

	December 31, 2025	December 31, 2024
Notes receivable	\$ 191,341	222,184
Other notes receivable	213,167	236,916
Accounts receivable	1,715,019	1,722,350
Receivable installments	809	4,070
Receivable installments - OCI	3,286	-
Lease payment receivable	440,703	346,980
Other receivables	3,039,008	3,428,145
Less: Loss allowance	(55,766)	(64,032)
Allowance for sales returns	(5,543)	(6,116)
Unrealized interests income	(113)	(172)
	<u>\$ 5,541,911</u>	<u>5,890,325</u>

The Group has assessed a portion of its trade receivables that was held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; therefore, such trade receivables were measured at fair value through other comprehensive income.

Arich Enterprise Co., Ltd. (“Arich”) engages in medical logistics services, providing inventory management services, logistics services, customer service and domestic transportation planning services. Arich recognizes the medical logistics service revenue at a percentage of the net profit on its sale of medicines. The inventories for medical logistics services do not belong to Arich. The receivables from customers and the payables to medical companies are classified as other notes receivable, other trade receivables, other notes payable, and other trade payables.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information, including macroeconomic and relevant industry information. The loss allowance provision were determined as follows:

	December 31, 2025		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Current	\$ 5,506,809	0.35%	(19,130)
1 to 90 days past due	64,103	13.35%	(8,557)
91 to 180 days past due	4,730	28.33%	(1,340)
181 to 365 days past due	1,639	49.05%	(804)
More than 365 days past due	25,939	99.98%	(25,935)
	\$ 5,603,220		(55,766)
	December 31, 2024		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Current	\$ 5,842,758	0.33%	(19,155)
1 to 90 days past due	70,118	7.41%	(5,199)
91 to 180 days past due	8,878	25.56%	(2,269)
181 to 365 days past due	2,205	48.71%	(1,074)
More than 365 days past due	36,514	99.51%	(36,335)
	\$ 5,960,473		(64,032)

The Group's lease payment receivables were as follows:

	Gross investment in the lease	Unearned finance income	Present value of minimum lease payments receivable
December 31, 2025			
Less than one year	\$ 124,683	(16,500)	108,183
Between one and five years	373,754	(41,234)	332,520
	\$ 498,437	(57,734)	440,703
December 31, 2024			
Less than one year	\$ 81,422	(14,285)	67,137
Between one and five years	321,455	(41,612)	279,843
	\$ 402,877	(55,897)	346,980

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group entered into finance lease arrangements for certain vehicles and equipment. All leases were denominated in New Taiwan dollars. The term of finance leases entered into was 1 to 5 years.

The lease payment receivables as of December 31, 2025 and 2024 were neither past due nor impaired.

The movement in the allowance for notes and trade receivable was as follows:

	For the Years Ended December 31,	
	2025	2024
Balance as of January 1	\$ 64,032	66,679
Impairment losses recognized (reversed)	(3,862)	492
Amounts written off	(3,558)	(3,690)
Effect of movements in exchange rate	(846)	551
Balance as of June 30	<u>\$ 55,766</u>	<u>64,032</u>

As of December 31, 2025 and 2024, the receivables from installment sales were \$4,095 thousand and \$4,070 thousand, respectively, and the related unrealized interest income were \$113 thousand and \$172 thousand, respectively.

(f) Inventories

	December 31,	December 31,
	2025	2024
Merchandise	\$ 1,359,048	1,368,680
Inventory in-transit	32,621	24,121
Total	<u>\$ 1,391,669</u>	<u>1,392,801</u>

The details of cost of goods sold were as follows :

	For the Years Ended December 31,	
	2025	2024
Cost of goods sold	\$ 6,037,147	5,827,479
(Reversal) losses on inventory valuation and obsolescence	(20,776)	20,341
Service Cost	303,013	270,040
Repair and maintenance costs	140,291	139,135
Others operating costs	455,190	500,228
Total	<u>\$ 6,914,865</u>	<u>6,757,223</u>

The factor leading to the net realizable value of inventories lower than the cost no longer exists, resulting in the net realizable value and the recognition of a gain on inventory recoveries for the December 31, 2025.

Inventory valuation and obsolescence due to write-down of inventory to net realizable value or slow-moving inventory were recognized as cost of operations for the year ended 2024.

As of December 31, 2025 and 2024, none of the combined company's inventories had been provided with pledge guarantees.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(g) Investments accounted for using equity method

A summary of the Group's financial information for investments accounted for using the equity method at the reporting date is as follows:

	December 31, 2025	December 31, 2024
Associates	\$ 4,216,105	4,041,150

1. Associates

Associates which are material to the Group consisted of the followings:

Name of Associates	Nature of Relationship with the Group	Main operating location/ Registered Country of the Company	Proportion of shareholding and voting rights	
			December 31, 2025	December 31, 2024
Asia Best Healthcare	Long-term care and rehabilitation services	Cayman Islands	48.47 %	48.47 %
Asia Best Life Care Co., Ltd.	Long-term care and rehabilitation services	Taiwan	49.02 %	49.38 %

1) Asia Best Healthcare:

	December 31, 2025	December 31, 2024
Current assets	\$ 1,026,727	840,369
Non-current assets	1,830,642	2,026,400
Current liabilities	(136,780)	(130,509)
Non-Current liabilities	(1,417,287)	(1,481,003)
Net assets	\$ 1,303,302	1,255,257
Net assets attributable to the Group	\$ 618,784	595,843
	For the Years Ended December 31,	
	2025	2024
Operating revenue	\$ 108,669	31,264
Profit	\$ 83,110	(18,408)
Other comprehensive income	16,019	(35,271)
Total comprehensive income	\$ 99,129	(53,679)
Comprehensive income attributable to the Group	\$ 48,048	(26,018)
Dividends received	\$ -	16,544

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Asia Best Life Care Co., Ltd.:

	December 31, 2025	December 31, 2024
Current assets	\$ 780,931	711,634
Non-current assets	1,650,824	2,032,035
Current liabilities	(117,647)	(179,989)
Non-Current liabilities	(317,861)	(696,270)
Net assets	<u>\$ 1,996,247</u>	<u>1,867,410</u>
Net assets attributable to the Group	<u>\$ 1,035,423</u>	<u>983,301</u>
	For the Years Ended December 31,	
	2025	2024
Operating revenue	<u>\$ 393,471</u>	<u>388,763</u>
Profit	\$ 140,361	101,009
Other comprehensive income	-	-
Total comprehensive income	<u>\$ 140,361</u>	<u>101,009</u>
Comprehensive income attributable to the Group	<u>\$ 69,188</u>	<u>49,878</u>
Dividends received	<u>\$ 25,390</u>	<u>25,390</u>

The Group's financial information for investments accounted for using equity method that are individually insignificant was as follows:

	December 31, 2025	December 31, 2024
Carrying amount of individually insignificant associates' equity	<u>\$ 2,561,898</u>	<u>2,462,006</u>
	For the Years Ended December 31,	
	2025	2024
Attributable to the Group		
Profit	\$ 294,946	282,238
Other comprehensive income	23,119	(40,907)
Total comprehensive income	<u>\$ 318,065</u>	<u>241,331</u>

None of the Group's investments using the equity method is provided as a pledge.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(h) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

Subsidiaries	Main operating location/ Registered Country of the Company	Proportion of shareholding and voting rights	
		December 31, 2025	December 31, 2024
Dynamic	Taiwan	66.03 %	66.04 %
Arich	Taiwan	60.00 %	60.00 %

The summarized financial information below represents amounts before intragroup eliminations were as follows:

1. Collective financial information of Dynamic and its subsidiaries:

	December 31, 2025	December 31, 2024
Current assets	\$ 1,878,616	1,906,632
Non-current assets	1,248,031	1,097,709
Current liabilities	(869,772)	(869,163)
Non-Current liabilities	(364,589)	(375,649)
Net assets	<u>\$ 1,892,286</u>	<u>1,759,529</u>
Non-controlling interests	<u>\$ 1,239,231</u>	<u>955,987</u>
	For the Years Ended December 31,	
	2025	2024
Operating revenue	<u>\$ 1,386,760</u>	<u>1,572,704</u>
Net income	\$ 179,759	238,057
Other comprehensive income	131,072	16,328
Total comprehensive income	<u>\$ 310,831</u>	<u>254,385</u>
Profit, attributable to non-controlling interests	<u>\$ 109,943</u>	<u>143,738</u>
Comprehensive income, attributable to non-controlling interests	<u>\$ 45,078</u>	<u>(11,011)</u>
	For the Years Ended December 31,	
	2025	2024
Net cash flows from operating activities	\$ 314,682	224,113
Net cash flows from investing activities	(47,882)	(61,592)
Net cash flows from financing activities	(268,243)	(379,008)
Effect of exchange rate changes on cash and cash equivalents	(2,102)	17,828
Net decrease in cash and cash equivalents	<u>\$ (3,545)</u>	<u>(198,659)</u>
Dividends paid to non-controlling interests	<u>\$ 99,481</u>	<u>136,980</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)
EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2. Collective financial information of Arich and its subsidiaries:

	December 31, 2025	December 31, 2024
Current assets	\$ 4,518,404	6,464,006
Non-current assets	741,319	639,998
Current liabilities	(3,132,231)	(5,041,639)
Non-Current liabilities	<u>(116,095)</u>	<u>(141,513)</u>
Net assets	<u>\$ 2,011,397</u>	<u>1,920,852</u>
Non-controlling interests	<u>\$ 1,206,816</u>	<u>1,152,489</u>
	For the Years Ended December 31,	
	2025	2024
Operating revenue	<u>\$ 1,546,999</u>	<u>1,297,767</u>
Net income	\$ 86,792	93,860
Other comprehensive income (loss)	<u>92,362</u>	<u>(126,870)</u>
Total comprehensive income	<u>\$ 179,154</u>	<u>(33,010)</u>
Profit, attributable to non-controlling interests	<u>\$ 52,075</u>	<u>56,316</u>
Comprehensive income, attributable to non-controlling interests	<u>\$ 107,492</u>	<u>(19,806)</u>
	For the Years Ended December 31,	
	2025	2024
Net cash flows from operating activities	\$ (1,903,634)	2,150,108
Net cash flows from investing activities	(16,682)	(68,490)
Net cash flows from financing activities	<u>402,842</u>	<u>(407,121)</u>
Net(decrease) increase in cash and cash equivalents	<u>\$ (1,517,474)</u>	<u>1,674,497</u>
Dividends paid to non-controlling interests	<u>\$ 53,166</u>	<u>41,151</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(i) Property, plant and equipment

The cost, depreciation, and impairment of the property, plant and equipment of the Group for the nine months ended December 31, 2025 and 2024 were as follows:

	Land	Buildings	Medical equipment	Miscellaneous equipment	Leased Improvement	Equipment to be inspected and construction in progress	Total
Cost or deemed cost:							
Balance as of January 1, 2025	\$ 144,507	238,277	539,855	563,532	15,726	39,018	1,540,915
Additions	-	-	9,862	35,828	-	31,946	77,636
Disposal and obsolescence	-	-	(144,799)	(23,450)	-	(7,868)	(176,117)
Transfer from inventories	-	-	74,136	23,728	-	-	97,864
Transfer to inventories	-	-	(15,518)	(5,707)	-	-	(21,225)
Transfer from prepayments	-	-	28,009	-	-	-	28,009
Reclassification and others	-	-	5,767	10,018	-	(14,788)	997
Effect of movements in exchange rates	4,240	10,156	512	833	-	(2,695)	13,046
Balance as of December 31, 2025	<u>\$ 148,747</u>	<u>248,433</u>	<u>497,824</u>	<u>604,782</u>	<u>15,726</u>	<u>45,613</u>	<u>1,561,125</u>
Balance as of January 1, 2024	\$ 137,822	226,572	524,453	504,021	10,657	24,547	1,428,072
Additions	-	-	26,129	49,347	393	38,997	114,866
Disposal and obsolescence	-	(4,095)	(28,683)	(12,974)	-	-	(45,752)
Transfer from inventories	-	-	108,106	13,857	-	-	121,963
Transfer to inventories	-	-	(43,667)	(1,397)	-	-	(45,064)
Transfer from prepayments	-	-	-	2,058	4,676	-	6,734
Reclassification and others	-	-	(53,789)	5,271	-	(24,548)	(73,066)
Effect of movements in exchange rates	6,685	15,800	7,306	3,349	-	22	33,162
Balance as of December 31, 2024	<u>\$ 144,507</u>	<u>238,277</u>	<u>539,855</u>	<u>563,532</u>	<u>15,726</u>	<u>39,018</u>	<u>1,540,915</u>
Depreciation and impairment losses:							
Balance as of January 1, 2025	\$ 4,000	75,608	284,765	377,414	3,531	-	745,318
Depreciation for the period	-	4,550	80,037	93,719	2,419	-	180,725
Disposal and obsolescence	-	-	(89,230)	(23,450)	-	-	(112,680)
Transfer to inventories	-	-	(9,093)	(3,867)	-	-	(12,960)
Reclassification and others	-	(225)	-	1,070	-	-	845
Effect of movements in exchange rates	-	2,892	348	632	-	-	3,872
Balance as of December 31, 2025	<u>\$ 4,000</u>	<u>82,825</u>	<u>266,827</u>	<u>445,518</u>	<u>5,950</u>	<u>-</u>	<u>805,120</u>
Balance as of January 1, 2024	\$ 4,000	70,952	278,778	300,428	1,302	-	655,460
Depreciation for the period	-	4,655	86,186	88,252	2,229	-	181,322
Disposal and obsolescence	-	(4,095)	(28,683)	(12,711)	-	-	(45,489)
Transfer to inventories	-	-	(40,510)	(1,290)	-	-	(41,800)
Reclassification and others	-	-	(16,381)	(172)	-	-	(16,553)
Effect of movements in exchange rates	-	4,096	5,375	2,907	-	-	12,378
Balance as of December 31, 2024	<u>\$ 4,000</u>	<u>75,608</u>	<u>284,765</u>	<u>377,414</u>	<u>3,531</u>	<u>-</u>	<u>745,318</u>
Carrying amount:							
Balance as of December 31, 2025	<u>\$ 144,747</u>	<u>165,608</u>	<u>230,997</u>	<u>159,264</u>	<u>9,776</u>	<u>45,613</u>	<u>756,005</u>
Balance as of January 1, 2024	<u>\$ 133,822</u>	<u>155,620</u>	<u>245,675</u>	<u>203,593</u>	<u>9,355</u>	<u>24,547</u>	<u>772,612</u>
Balance as of December 31, 2024	<u>\$ 140,507</u>	<u>162,669</u>	<u>255,090</u>	<u>186,118</u>	<u>12,195</u>	<u>39,018</u>	<u>795,597</u>

As of December 31, 2025 and 2024 the property, plant and equipment of the Group had been pledged as collateral for bank borrowings. Please refer to note(8).

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(j) Right-of-use assets

The Group leases many assets including buildings, machinery and other equipment. Information about leases for which the Group as a lessee was presented below:

	<u>Buildings</u>	<u>Machinery and equipment</u>	<u>Other equipment</u>	<u>Total</u>
Cost:				
Balance as of January 1, 2025	\$ 551,249	7,737	-	558,986
Additions	229,955	4,539	410	234,904
Write-off	(187,195)	(2,249)	-	(189,444)
Effect of movements in exchange rates	(1,755)	-	(6)	(1,761)
Balance as of December 31, 2025	<u>\$ 592,254</u>	<u>10,027</u>	<u>404</u>	<u>602,685</u>
Balance as of January 1, 2024	\$ 468,383	5,873	-	474,256
Additions	295,140	1,864	-	297,004
Write-off	(212,912)	-	-	(212,912)
Effect of movements in exchange rates	638	-	-	638
Balance as of December 31, 2024	<u>\$ 551,249</u>	<u>7,737</u>	<u>-</u>	<u>558,986</u>
Accumulated depreciation and impairment losses:				
Balance as of January 1, 2025	\$ 229,593	3,774	-	233,367
Depreciation for the year	109,762	3,062	198	113,022
Write-off	(13,323)	(2,249)	-	(15,572)
Effect of movements in exchange rates	(243)	-	(3)	(246)
Balance as of December 31, 2025	<u>\$ 325,789</u>	<u>4,587</u>	<u>195</u>	<u>330,571</u>
Balance as of January 1, 2024	\$ 174,057	1,505	-	175,562
Depreciation for the year	102,314	2,269	-	104,583
Write-off	(47,110)	-	-	(47,110)
Effect of movements in exchange rates	332	-	-	332
Balance as of December 31, 2024	<u>\$ 229,593</u>	<u>3,774</u>	<u>-</u>	<u>233,367</u>
Carrying amount:				
Balance as of December 31, 2025	<u>\$ 266,465</u>	<u>5,440</u>	<u>209</u>	<u>272,114</u>
Balance as of January 1, 2024	<u>\$ 294,326</u>	<u>4,368</u>	<u>-</u>	<u>298,694</u>
Balance as of December 31, 2024	<u>\$ 321,656</u>	<u>3,963</u>	<u>-</u>	<u>325,619</u>

For the years ended 2025 and 2024, the Group leases storage room, machinery and parking space under operating lease, please refer to Note (6)(q).

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(k) Investment property

Investment properties are the assets hold by the Group. The period of rental investment properties that cannot be terminated originally is 15 years.

	<u>Owned property</u>		<u>Total</u>
	<u>Land</u>	<u>Buildings</u>	
Cost or deemed cost:			
Balance as of January 1, 2025	\$ 1,266,920	386,921	1,653,841
Balance as of December 31, 2025	<u>\$ 1,266,920</u>	<u>386,921</u>	<u>1,653,841</u>
Balance as of January 1, 2024	\$ 920,080	215,947	1,136,027
Addition	288,544	141,216	429,760
Reclassification	58,296	29,758	88,054
Balance as of December 31, 2024	<u>\$ 1,266,920</u>	<u>386,921</u>	<u>1,653,841</u>
Depreciation and impairment losses:			
Balance as of January 1, 2025	\$ -	43,296	43,296
Depreciation for the year	-	12,303	12,303
Balance as of December 31, 2025	<u>\$ -</u>	<u>55,599</u>	<u>55,599</u>
Balance as of January 1, 2024	\$ -	34,225	34,225
Depreciation for the year	-	9,071	9,071
Balance as of December 31, 2024	<u>\$ -</u>	<u>43,296</u>	<u>43,296</u>
Book value:			
Balance as of December 31, 2025	<u>\$ 1,266,920</u>	<u>331,322</u>	<u>1,598,242</u>
Balance as of January 1, 2024	<u>\$ 920,080</u>	<u>181,722</u>	<u>1,101,802</u>
Balance as of December 31, 2024	<u>\$ 1,266,920</u>	<u>343,625</u>	<u>1,610,545</u>
Fair Value:			
Balance as of December 31, 2025			<u>\$ 1,939,658</u>
Balance as of December 31, 2024			<u>\$ 1,896,413</u>

The fair value of investment properties was based on a valuation by a qualified independent appraiser. Fair value was measured using comparison approach, income approach and cost approach.

As of December 31, 2025 and 2024, the investment property of the Group had been pledged as collateral, please refer to Note (8).

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(l) Intangible assets

	<u>Goodwill</u>	<u>Software</u>	<u>Other intangible assets</u>	<u>Total</u>
Cost:				
Balance as of January 1, 2025	\$ 59,540	24,783	31,680	116,003
Additions	-	5,251	-	5,251
Disposals	-	(3,010)	-	(3,010)
Effect of movements in exchange rates	<u>5,012</u>	<u>(139)</u>	<u>-</u>	<u>4,873</u>
Balance as of December 31, 2025	<u>\$ 64,552</u>	<u>26,885</u>	<u>31,680</u>	<u>123,117</u>
Balance as of January 1, 2024	\$ 56,304	18,927	31,680	106,911
Additions	-	5,828	-	5,828
Effect of movements in exchange rates	<u>3,236</u>	<u>28</u>	<u>-</u>	<u>3,264</u>
Balance as of December 31, 2024	<u>\$ 59,540</u>	<u>24,783</u>	<u>31,680</u>	<u>116,003</u>
Amortization and impairment loss:				
Balance as of January 1, 2025	\$ 30,595	16,021	22,263	68,879
Amortization	-	4,345	1,624	5,969
Disposals	-	(3,010)	-	(3,010)
Effect of movements in exchange rates	<u>4,568</u>	<u>(46)</u>	<u>-</u>	<u>4,522</u>
Balance as of December 31, 2025	<u>\$ 35,163</u>	<u>17,310</u>	<u>23,887</u>	<u>76,360</u>
Balance as of January 1, 2024	\$ 28,059	13,062	20,639	61,760
Amortization	-	2,948	1,624	4,572
Effect of movements in exchange rates	<u>2,536</u>	<u>11</u>	<u>-</u>	<u>2,547</u>
Balance as of December 31, 2024	<u>\$ 30,595</u>	<u>16,021</u>	<u>22,263</u>	<u>68,879</u>
Book value:				
Balance as of December 31, 2025	<u>\$ 29,389</u>	<u>9,575</u>	<u>7,793</u>	<u>46,757</u>
Balance as of January 1, 2024	<u>\$ 28,245</u>	<u>5,865</u>	<u>11,041</u>	<u>45,151</u>
Balance as of December 31, 2024	<u>\$ 28,945</u>	<u>8,762</u>	<u>9,417</u>	<u>47,124</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

1. Amortization

The amortization of intangible assets is included in the following statement of comprehensive income items:

	For the Years Ended December 31,	
	2025	2024
Operating costs	\$ 622	1,384
Operating expenses	5,347	3,188
Total	<u>\$ 5,969</u>	<u>4,572</u>

(m) Long and short-term borrowings

	December 31,	December 31,
	2025	2024
Secured bank loans	\$ 732,000	614,500
Unsecured bank loans	961,221	303,031
Total	<u>\$ 1,693,221</u>	<u>917,531</u>
Unused credit lines	<u>\$ 3,446,199</u>	<u>4,847,754</u>
Range of interest rates	<u>1.73%~6.45%</u>	<u>1.76%~7.53%</u>

Please refer to Note (8) for details of the Group's assets pledged as collateral for bank borrowings.

The Group's interest risk and sensitivity analysis of financial assets and liabilities were disclosed in Note (6)(y).

(n) Other payables

	December 31,	December 31,
	2025	2024
Logistics services payable	\$ 2,110,545	4,606,255
Others	485,784	701,014
	<u>\$ 2,596,329</u>	<u>5,307,269</u>

(o) Provisions

	December 31,	December 31,
	2025	2024
Warranties	\$ 16,628	18,241

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	<u>Warranties</u>
Balance as of January 1, 2025	\$ 18,241
Additions	17,890
Provisions reversed or used	<u>(19,503)</u>
Balance as of December 31, 2025	<u>\$ 16,628</u>
Balance as of January 1, 2024	\$ 14,922
Additions	19,552
Provisions reversed or used	<u>(16,233)</u>
Balance as of December 31, 2024	<u>\$ 18,241</u>

Warranties

The provision for warranty claims represents the present value of management's best estimate of the future outflow of economic benefits that will be required under the Group's obligations for warranties under local sale of goods legislation. The estimate had been made on the basis of historical warranty trends and may vary as a result of other events affecting product quality.

(p) Lease liabilities

The carrying amounts of lease liabilities were as follows:

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Current	<u>\$ 140,406</u>	<u>128,343</u>
Non-current	<u>\$ 320,279</u>	<u>377,827</u>

For the maturities analysis, please refer to Note (6)(y).

The amounts recognized in profit or loss were as follows:

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Interest on lease liabilities	<u>\$ 7,888</u>	<u>5,091</u>
Income from sub-leasing right-of-use assets	<u>\$ 21,325</u>	<u>22,442</u>
Expenses relating to short-term leases	<u>\$ 11,642</u>	<u>35,693</u>

The amounts recognized in the statement of cash flows for the Group were as follows:

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Total cash outflow for leases	<u>\$ 156,814</u>	<u>142,053</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

1. Buildings leases

The Group leases buildings for its office space. The leases of office space typically run for a period of 2 to 10 years. Some leases include an option to renew the lease for an additional period of the same duration after the end of the contract term.

The Group sub-leases some of its right-of-use assets under operating leases; please refer to Note (6)(q).

2. Other leases

The Group leases machinery and other equipment, with lease terms of 1 to 5 years. In some cases, the Group has options to purchase the assets at the end of the contract term.

The Group also leases storage room, machinery and parking space with contract terms of 1 year to 3 years. These leases are short-term or leases of low-value items. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases.

(q) Operating leases

Operating leases relate to leases and subleases of housing and leases of equipments with lease terms between 1 to 10 years. The lessees does not have bargain purchase options to acquire the leased housing and equipments at the expiration of the lease periods.

A maturity analysis of lease payments, showing the undiscounted lease payments to be received after the reporting date are as follows:

	December 31, 2025	December 31, 2024
Within 1 year	\$ 11,541	31,166
1 to 5 years	1,403	69,935
More than 5 years	-	8,039
	<u>\$ 12,944</u>	<u>109,140</u>

(r) Employee benefits

1. Defined benefit plans

Reconciliation of defined benefit obligation at present value and plan asset at fair value were as follows:

	December 31, 2025	December 31, 2024
Present value of defined benefit obligations	\$ 83,836	78,845
Fair value of plan assets	(141,343)	(128,427)
Net defined benefit liabilities	<u>(57,507)</u>	<u>(49,582)</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group makes defined benefit plan contributions to the pension fund account with Bank of Taiwan that provides pensions for employees upon retirement. The plans (covered by the Labor Standards Law) entitle a retired employee to receive retirement benefits based on years of service and average salary for the six months prior to retirement.

1) Composition of plan assets

The Group allocates pension funds in accordance with the Regulations for Revenues, Expenditures, Safeguard and Utilization of the Labor Retirement Fund, and such funds are managed by the Bureau of Labor Funds, Ministry of Labor. With regard to the utilization of the funds, minimum earnings shall be no less than the earnings attainable from two-year time deposits with interest rates offered by local banks.

The Group's Bank of Taiwan labor pension reserve account balance amounted to \$139,853 thousand as of December 31, 2025. For information on the utilization of the labor pension fund assets, including the asset allocation and yield of the fund, please refer to the website of the Bureau of Labor Funds, Ministry of Labor.

2) Movements in present value of the defined benefit obligations

The movements in present value of defined benefit obligations for the Group were as follows:

	For the Years Ended December 31,	
	2025	2024
Defined benefit obligations as of January 1	\$ 78,845	95,315
Current service costs and interest	2,811	3,621
Remeasurements on the net defined benefit obligation		
— Actuarial gains and losses arising from experience adjustments	861	(17,143)
— Actuarial gains and losses arising from changes in financial assumptions	1,998	(1,680)
Exchange differences on foreign plans	(55)	75
Benefit paid	(624)	(1,343)
Defined benefit obligations as of December 31	<u>\$ 83,836</u>	<u>78,845</u>

3) Movements of defined benefit plan assets

The movements in the present value of the defined benefit plan assets for the Group were as follows:

	For the Years Ended December 31,	
	2025	2024
Fair value of plan assets as of January 1	\$ 128,427	115,768
Interest income	2,052	1,513
Remeasurement on the net defined benefit obligation		
— Return on plan assets (excluding current interest)	8,912	10,152
Contribution paid by the employer	1,266	2,337
Contribution by plan participants	1,310	-
Benefits paid	(624)	(1,343)
Fair value of plan assets as of December 31	<u>\$ 141,343</u>	<u>128,427</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4) Expenses recognized in profit or loss

The expenses recognized in profit or loss for the Group were as follows:

	For the Years Ended December 31,	
	2025	2024
Current service costs	\$ 1,615	2,170
Net interest of net liabilities for defined benefit obligations	(855)	(281)
	\$ 760	1,889
Operating costs and expenses	\$ 760	1,889

5) Actuarial assumptions

The principal actuarial assumptions at the reporting date were as follows:

	December 31, 2025	December 31, 2024
Discount rate	1.000%-4.060%	1.000%-1.600%
Future salary increasing rate	1.000%-3.750%	1.000%-3.750%

The expected allocation payment to be made by the Group to the defined benefit plans for the one-year period after the reporting date is \$1,596 thousand.

The weighted average lifetime of the defined benefits plans is 7~11 years.

6) Sensitivity analysis

If the actuarial assumptions had changed, the impact on the present value of the defined benefit obligation shall be as follows:

	Influences on defined benefit obligations	
	Increased 0.25% and EG Healthcare Increased 1.00%	Decreased 0.25% and EG Healthcare Decreased 1.00%
December 31, 2025		
Discount rate	\$ (1,628)	1,728
Future salary increasing rate	1,674	(1,584)
December 31, 2024		
Discount rate	\$ (1,432)	1,473
Future salary increasing rate	1,421	(1,386)

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown above. The method used in the sensitivity analysis is consistent with the calculation of the pension liabilities in the balance sheets.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

There is no change in the method and assumptions used in the preparation of sensitivity analysis for 2025 and 2024.

2. Defined contribution plans

The Company allocates 6% of each employee's monthly wages to the labor pension personal account at the Bureau of Labor Insurance in accordance with the provisions of the Labor Pension Act. Under these defined contribution plans, the Company allocates a fixed amount to the Bureau of Labor Insurance without additional legal or constructive obligation.

The pension costs incurred from the contributions to the Bureau of the Labor Insurance amounted to \$34,417 thousand and \$32,257 thousand for the years ended December 31, 2025 and 2024, respectively.

The foreign Company's pension costs under the local laws were \$2,433 thousand and \$3,106 thousand for the years ended December 31, 2025 and 2024, respectively.

(s) Income taxes

1. Income tax expense

The components of income tax for the years ended 2025 and 2024 were as follows:

	For the Years Ended December 31,	
	2025	2024
Current tax expense		
Current period	\$ 214,016	195,884
Adjustment for prior periods	907	(8,320)
	<u>214,923</u>	<u>187,564</u>
Deferred tax expense		
Origination and reversal of temporary differences	(566)	11,482
Adjustment for prior periods	1,814	3,880
Change in unrecognized deductible temporary differences	129	381
	<u>1,377</u>	<u>15,743</u>
Income tax expense from continuing operations	\$ 216,300	203,307

The amount of income tax recognized directly in equity for 2025 was as follows; no income tax was recognized directly in equity for 2024:

	For the Years Ended December 31,	
	2025	2024
Gain on disposal of foreign listed shares	\$ 8,115	-

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The amounts of income tax recognized in other comprehensive income for the years ended 2025 and 2024 were as follows:

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Items that will not be reclassified subsequently to profit or loss:		
Remeasurement from defined benefit plans	\$ (1,172)	(6,418)
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income	(54,442)	(63,160)
	<u>\$ (55,614)</u>	<u>(69,578)</u>
Items that may be reclassified subsequently to profit or loss:		
Exchange differences on translation	<u>8,671</u>	<u>(30,695)</u>

Reconciliation of income tax and profit before tax for 2025 and 2024 were as follows:

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Profit before income tax	\$ 1,181,907	1,174,362
Income tax using the Group's domestic tax rate	\$ 289,914	280,084
Permanent differences	(69,529)	(69,791)
Tax-exempt income	(810)	(491)
Unrecognized deductible temporary differences	(6,262)	1,448
Unrecognized unused loss carryforwards	-	(4,840)
Adjustments for prior periods-current tax expense	2,721	(4,440)
Undistributed earnings additional tax	266	1,337
Income tax expense	<u>\$ 216,300</u>	<u>203,307</u>

2. Deferred tax assets and liabilities

1) Unrecognized deferred tax assets

Deferred tax assets have not been recognized in respect of the following items:

	<u>December 31,</u>	<u>December 31,</u>
	<u>2025</u>	<u>2024</u>
Tax effect of deductible temporary differences	\$ 14,562	18,604
Tax losses	51,259	29,306
	<u>\$ 65,821</u>	<u>47,910</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Recognized deferred tax assets and liabilities

Changes in the amount of deferred tax assets and liabilities for the years ended December 31, 2025 and 2024 were as follows:

	Deferred sales returns and allowance	Unrealized losses on inventories	Unrealized gains on investment	Loss carry- forwards	Others	Total
Deferred tax liabilities:						
Balance as of January 1, 2025	\$ 10,002	27,833	-	1,694	69,032	108,561
Recognized in profit or loss	7,887	(3,939)	-	(140)	1,206	5,014
Recognized in other comprehensive income	-	-	-	-	2,142	2,142
Effect of movements in exchange rates	(100)	6	-	-	(268)	(362)
Balance as of December 31, 2025	<u>\$ 17,789</u>	<u>23,900</u>	<u>-</u>	<u>1,554</u>	<u>72,112</u>	<u>115,355</u>
Balance as of January 1, 2024	\$ 17,247	24,595	1,649	1,872	91,635	136,998
Recognized in profit or loss	(7,247)	3,256	(1,649)	(178)	(3,024)	(8,842)
Recognized in other comprehensive income	-	-	-	-	(19,760)	(19,760)
Effect of movements in exchange rates	2	(18)	-	-	181	165
Balance as of December 31, 2024	<u>\$ 10,002</u>	<u>27,833</u>	<u>-</u>	<u>1,694</u>	<u>69,032</u>	<u>108,561</u>
Deferred tax assets:						
Balance as of January 1, 2025	\$ -	-	217,529	-	104,957	322,486
Recognized in profit or loss	-	-	8,331	-	(1,940)	6,391
Recognized in other comprehensive income	-	-	-	-	49,085	49,085
Recognized directly in equity	-	-	-	-	(8,115)	(8,115)
Balance as of December 31, 2025	<u>\$ -</u>	<u>-</u>	<u>225,860</u>	<u>-</u>	<u>143,987</u>	<u>369,847</u>
Balance as of January 1, 2024	\$ -	-	212,954	-	22,118	235,072
Recognized in profit or loss	-	-	4,575	-	2,326	6,901
Recognized in other comprehensive income	-	-	-	-	80,513	80,513
Balance as of December 31, 2024	<u>\$ -</u>	<u>-</u>	<u>217,529</u>	<u>-</u>	<u>104,957</u>	<u>322,486</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3. As of December 31, 2025, the Group's unused prior-years loss carryforwards and the expiry years of the loss carryforwards were as follows:

<u>Year of loss</u>	<u>Unused tax loss</u>	<u>Year of expiry</u>
2018	\$ 39,883	2023~2028
2019	148,077	2024~2029
2020	3,966	2025~2030
2022	21,526	2029~2032
2023	385	2030~2033
	<u>\$ 213,837</u>	

4. Assessment of tax

The Company's income tax returns for the years through 2023 were assessed by the Tax Administration.

(t) Capital and other equity

1. Share capital

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Number of shares authorized (in thousands)	<u>200,000</u>	<u>200,000</u>
Shares authorized	<u>\$ 2,000,000</u>	<u>2,000,000</u>
Number of shares issued and fully paid (in thousands)	<u>171,567</u>	<u>163,398</u>
Shares issued	<u>\$ 1,715,674</u>	<u>1,633,975</u>

The Company issued 8,170 thousand common shares amounting to \$81,699 thousand, with the date of capital increase set on September 9, 2025, based on the resolution decided during the shareholders' meeting held on June 26, 2025, and the approval of the Financial Supervisory Commission, R.O.C. on August 18, 2025. All relevant statutory registration procedures have been completed as of the reporting date.

The Company issued 7,781 thousand common shares amounting to \$77,808 thousand, with the date of capital increase set on September 1, 2024, based on the resolution decided during the shareholders' meeting held on June 21, 2024, and the approval of the Financial Supervisory Commission, R.O.C. on July 30, 2024. All relevant statutory registration procedures have been completed as of the reporting date.

A total of 10,000 thousand shares of the Company's authorized shares are reserved for the issuance of employee share options, convertible bonds with warrants and preferred shares with warrants.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2. Capital surplus

	December 31, 2025	December 31, 2024
Additional paid-in capital arising from ordinary share	\$ 1,822,584	1,822,584
Additional paid-in capital arising from bond conversion	1,072,079	1,072,079
Difference between consideration and carrying amount of subsidiaries acquired or disposed	193,054	193,054
Changes in ownership interest in subsidiaries	250,941	250,872
Changes in equity of associates accounted for using equity method	8,315	339
Others	43,860	43,860
	<u>\$ 3,390,833</u>	<u>3,382,788</u>

3. Retained earnings

The Company's article of incorporation stipulates that Company's profit after tax should first be used to offset the prior years' deficits, including adjustment of unappropriated retained earnings and 10% of the rest be set aside as legal reserve, then the special surplus reserve shall be distributed or reversed according to the Laws acts and regulations approved by the Competent authority. The remainder, together with any undistributed retained earnings, including amount of adjusted retained earnings, shall be distributed by the Board of Directors and submitted to the stockholders' meeting for approval. The distribution of dividends, bonus, legal reserve and capital surplus, distributed by way of cash, shall be decided during the Board meeting, approved by more than half of the directors, with two thirds of directors in attendance; thereafter, to be submitted in the shareholders' meeting of the Company.

The Company's Articles also stipulate a dividend policy which is as follows: According to the present and future development plans, the investment environment, capital requirements, domestic and overseas competition, and the benefit of shareholders, the Company should distribute dividends and bonuses to shareholders at no less than 20% of the remaining profit (which is the current net profit less losses of previous years, less the adjustment to retained earnings, and less 10% of its after-tax annual earnings as legal reserve). Dividends could be distributed in cash or shares, where cash dividends should not be less than 20% of the total dividends distributed.

According to the amendment of the R.O.C. Company Act in January 2012, the Company must retain 10% of its after-tax annual earnings as legal reserve until such retention equals the amount of total capital. When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The amounts of cash dividends on the 2024 and 2023 earnings distribution had been approved during the board meeting on March 7, 2025 and March 8, 2024, respectively. The amounts of stock dividends on the 2024 and 2023 earnings distribution had been approved during the shareholders' meeting on June 26, 2025 and June 21, 2024, respectively, as follows:

	<u>2024</u>		<u>2023</u>	
	<u>Dividend per share (\$)</u>	<u>Amount</u>	<u>Dividend per share (\$)</u>	<u>Amount</u>
Dividends distributed to common shareholders				
Cash	\$ 3.80	620,910	3.80	591,344
Share	0.50	<u>81,699</u>	0.50	<u>77,808</u>
Total		<u>\$ 702,609</u>		<u>669,152</u>

The amount of cash dividends on the appropriations of earnings for 2025 had been approved and proposed, respectively during the Board meeting on March 6, 2026, as follows:

	<u>2025</u>	
	<u>Dividend per share (\$)</u>	<u>Amount</u>
Dividends distributed to common shareholders		
Cash	\$ 4.30	<u>809,980</u>
Total		<u>\$ 809,980</u>

4. Other equity interest after tax

	<u>Exchange differences on translation of foreign financial statements</u>	<u>Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income</u>
Balance as of January 1, 2025	\$ (10,729)	344,217
Exchange differences on translation of foreign financial statement	(84,686)	-
Exchange differences on associates accounted for using equity method	51,748	-
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	-	75,570
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income, associates accounted for using equity method	-	(20,109)
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	<u>(11,066)</u>
Balance as of December 31, 2025	<u>\$ (43,667)</u>	<u>388,612</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income
Balance as of January 1, 2024	\$ (122,201)	388,865
Exchange differences on translation of foreign financial statement	183,681	-
Exchange differences on associates accounted for using equity method	(72,209)	-
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	-	(58,853)
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income, associates accounted for using equity method	-	14,205
Balance as of December 31, 2024	<u>\$ (10,729)</u>	<u>344,217</u>

5. Non-controlling interests after tax

	For the Years Ended December 31,	
	2025	2024
Balance, beginning of year	\$ 2,387,112	2,299,950
Shares attributed to non-controlling interests		
Net income	159,747	199,796
Exchange differences on translation of foreign financial statements	(24,611)	81,844
Unrealized gains or losses from financial assets measured at fair value through other comprehensive income	143,719	(79,208)
Gains or losses on remeasurements of defined benefit plans	(66)	3,026
Cash dividends of subsidiaries distributed to non controlling interests	(154,997)	(182,452)
Disposal of equity instruments measure at fair value through other comprehensive income	21,434	-
Acquired the non controlling interests from the acquisition of subsidiaries	(18)	(57)
Gain on non-controlling interests from the disposal of subsidiaries	-	64,213
Balance, end of year	<u>\$ 2,532,320</u>	<u>2,387,112</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(u) Earnings per share

For the years ended 2025 and 2024, the basic and diluted earnings per share were calculated as follows:

1. Basic earnings per share

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Profit attributable to ordinary shareholders of the Company	<u>\$ 805,860</u>	<u>771,259</u>
Weighted average number of ordinary shares (basic)(retroactive adjustments)	<u>171,567</u>	<u>171,567</u>

2. Diluted earnings per share

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Profit attributable to ordinary shareholders of the Company	<u>\$ 805,860</u>	<u>771,259</u>
Weighted average number of ordinary shares (basic)(retroactive adjustments)	171,567	171,567
Effect of employee stock compensation	<u>720</u>	<u>656</u>
Weighted average number of ordinary shares (diluted)(retroactive adjustments)	<u>172,287</u>	<u>172,223</u>

(v) Revenue from contracts with customers

1. Disaggregation of revenue

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Primary geographical markets:		
Taiwan	\$ 8,094,473	8,067,217
Hong Kong	4,473	22,811
China	17,807	4,418
Philippines	543,837	293,876
Malaysia	75,406	70,265
Indonesia	<u>53,240</u>	<u>79,959</u>
	<u>\$ 8,789,236</u>	<u>8,538,546</u>
Major products:		
Product revenue		
Medical equipment and Supplies	\$ 4,994,418	4,951,991
Medicines	1,231,081	946,659
Aesthetic medical equipment and Supplies	995,012	1,160,314
Household appliances	164,894	161,296
Other	109,309	52,320
Repair and maintenance revenue	586,071	554,592
Other operating revenue	<u>708,451</u>	<u>711,374</u>
	<u>\$ 8,789,236</u>	<u>8,538,546</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2. Contract balances

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>	<u>January 1,</u> <u>2024</u>
Notes receivable, accounts receivable, lease payment receivable and other receivables	\$ 5,597,677	5,954,357	5,939,286
Less: allowance for impairment	<u>(55,766)</u>	<u>(64,032)</u>	<u>(66,679)</u>
Total	<u>\$ 5,541,911</u>	<u>5,890,325</u>	<u>5,872,607</u>
Contract liabilities	<u>\$ 572,217</u>	<u>543,595</u>	<u>559,166</u>

For details on trade receivables and allowance for impairment, please refer to note (6)(e).

The amount of revenue recognized for the years ended 2025 and 2024 that was included in the contract liability balance at the beginning of the period were \$225,240 thousand and \$285,115 thousand, respectively.

(w) Employee compensation and directors' remuneration

In accordance with the Articles of Incorporation, the Company should contribute no less than 1% of the profit as employee compensation and no higher than 5% as directors' remuneration when there is profit for the year. However, if the Company has accumulated deficits, the profit should be reserved to offset the deficits. The amount of compensation for employees may be paid by shares or cash, and the recipients may include the employees of the Company's affiliated companies. The amount of remuneration to directors may only be paid in cash. Both the employee compensation and directors' remuneration should be approved by the Board of Directors and reported during the shareholders' meeting.

For the years ended December 31, 2025 and 2024, the Company estimated its employee compensation amounting to \$50,271 thousand and \$47,985 thousand, and directors' remuneration amounting to \$25,136 thousand and \$23,992 thousand, respectively. The estimated amounts mentioned above are calculated based on the net profit before tax, excluding the compensation to employees and remuneration to directors of each period, multiplied by the percentage specified in the Company's articles. These remunerations were expensed under operating costs or operating expenses during 2025 and 2024. Related information would be available at the Market Observation Post System website. The aforesaid amounts are identical to those stated in parent-company-only financial statements.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)
EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(x) Non-operating income and expenses

1. Interest Income

The details of other income were as follows:

	For the Years Ended December 31,	
	2025	2024
Interest income from bank deposits	\$ 54,681	69,717
Interest income from lease payment receivable	20,889	6,997
Other interest income	11	22
Total	\$ 75,581	76,736

2. Other income

The details of other income were as follows:

	For the Years Ended December 31,	
	2025	2024
Dividend income	\$ 9,371	16,821
Other income	4,110	5,525
	\$ 13,481	22,346

3. Financial costs

The details of financial costs were as follows:

	For the Years Ended December 31,	
	2025	2024
Bank borrowings	\$ 22,135	18,653
Others	12,783	8,463
	\$ 34,918	27,116

4. Other gains and losses

The details of other gains and losses were as follows:

	For the Years Ended December 31,	
	2025	2024
Gains (losses) on disposal of property, plant, and equipment	-	764
Foreign exchange (losses) gains	\$ (18,420)	6,296
Net gains or losses on financial assets (liabilities) measured at fair value through profit or loss	1,135	1,855
Others	16,092	16,972
	\$ (1,193)	25,887

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(y) Financial instruments

1. Credit risks

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

2) Concentration of credit risk

To minimize credit risks of receivables, the Group periodically evaluates the customers' financial positions and the possibility of collecting trade receivables. And, the impairment losses are always within the management's expectation. As of December 31, 2025 and 2024, 47% and 44%, respectively, of notes receivable and accounts receivable were two customers. Thus, credit risk is significantly centralized.

2. Liquidity risks

The following are the contractual maturities of financial liabilities of the Group, including estimated interest payments and excluding the impact of netting arrangements:

	Carrying amount	Contractual cash flow	On Demand or Less than 1 month	1-3 months	3-6 months	6-12 months	1-2 years	More than 2 years
December 31, 2025								
Non-derivative financial liabilities								
Short-term borrowings	\$ 1,343,221	1,344,055	950,236	393,819	-	-	-	-
Payables	3,742,683	3,742,683	819,879	2,797,534	38,303	86,967	-	-
Lease liabilities	460,685	462,806	12,224	23,547	35,334	70,347	91,710	229,644
Long-term borrowings	350,000	482,868	583	1,166	1,748	3,497	6,993	468,881
Deposits received	9,513	9,513	-	-	-	-	-	9,513
	<u>\$ 5,906,102</u>	<u>6,041,925</u>	<u>1,782,922</u>	<u>3,216,066</u>	<u>75,385</u>	<u>160,811</u>	<u>98,703</u>	<u>708,038</u>
December 31, 2024								
Non-derivative financial liabilities								
Short-term borrowings	\$ 917,531	919,726	257,090	662,636	-	-	-	-
Payables	6,286,239	6,286,239	929,916	5,206,955	62,267	87,091	-	10
Lease liabilities	506,170	509,391	33,792	13,102	20,253	62,931	120,351	258,962
Deposits received	11,148	11,148	-	-	-	-	-	11,148
	<u>\$ 7,721,088</u>	<u>7,726,504</u>	<u>1,220,798</u>	<u>5,882,693</u>	<u>82,520</u>	<u>150,022</u>	<u>120,351</u>	<u>270,120</u>

The Group is not expecting that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3. Market risks

1) Currency risks

The Group's significant exposure to foreign currency risk of financial assets and liabilities were as follows:

<u>Functional currency</u>	<u>Exchange rate</u>	<u>Currency</u>	<u>December 31, 2025</u>	
			<u>Foreign currency (in thousands)</u>	<u>Carrying amount (TWD)</u>
<u>Financial assets</u>				
<u>Monetary items</u>				
TWD	31.430	USD	\$ 3,647	114,622
TWD	0.201	JPY	63,280	12,706
HKD	4.038	USD	11,835	371,969
MYR	4.202	USD	573	18,010
<u>Non-Monetary items</u>				
TWD	0.022	KRW	10,415,732	229,146
USD	0.032	TWD	732,962	732,962
USD	0.143	CNY	6,747	30,326
USD	0.129	HKD	249,794	1,008,855
USD	0.238	MYR	43,086	322,296
USD	0.017	PHP	289,392	154,625
<u>Financial liabilities</u>				
<u>Monetary items</u>				
TWD	0.201	JPY	290,667	58,366
TWD	31.430	USD	1,590	49,973
PHP	58.913	USD	1,769	55,600

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

<u>Functional currency</u>	<u>Exchange rate</u>	<u>Currency</u>	<u>December 31, 2024</u>	
			<u>Foreign currency (in thousands)</u>	<u>Carrying amount (TWD)</u>
<u>Financial assets</u>				
<u>Monetary items</u>				
TWD	32.785	USD	\$ 15,225	499,144
TWD	0.210	JPY	71,177	14,940
TWD	34.140	EUR	383	13,079
<u>Non-Monetary items</u>				
TWD	0.023	KRW	4,968,000	111,581
USD	0.031	TWD	723,565	723,565
USD	0.137	CNY	31,857	142,670
USD	0.129	HKD	269,642	1,138,621
USD	0.216	MYR	44,839	316,797
USD	0.017	PHP	168,922	95,809
<u>Financial liabilities</u>				
<u>Monetary items</u>				
TWD	32.785	USD	2,640	86,552

Since the Group has many kinds of currency, the information on foreign exchange gains or losses on monetary items is disclosed by total amount. For the years ended 2025 and 2024, foreign exchange gains or losses amounted to losses of \$18,420 thousand and gains of \$6,296 thousand, respectively.

2) Sensitivity analysis

The Group's foreign exchange exposure to foreign currency risk arises from foreign currency exchange fluctuations on cash and cash equivalents, accounts receivables and accounts payables. Assuming other variables remain the same, a 1% depreciation or appreciation of the TWD against foreign currency as of December 31, 2025 and 2024 would have increased or decreased the net profit after tax by \$3,370 thousand and \$3,002 thousand, respectively. The analysis is performed on the same basis for both periods.

3) Interest rate risk

The Group's financial assets and financial liabilities with interest rate exposure risk were noted in the liquidity risk section.

The following sensitivity analysis is based on the exposure to the interest rate risk of derivative and non-derivative financial instruments on the reporting date. Regarding liabilities with variable interest rates, the analysis is based on the assumption that the amount of liabilities outstanding at the reporting date was outstanding throughout the year.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

If the interest rate increases or decreases by 1%, assuming that all other variables remain constant, the Group's net profit after tax will increase or decrease by \$8,696 thousand and \$17,450 thousand for the years ended 2025 and 2024, respectively. The changes are mainly due to floating rate bank deposits and borrowings of the Group.

4) Other price risks

Assuming that the analysis is performed on the same basis for both periods, if equity prices had been 1% higher/lower, pre-tax other comprehensive income for the years ended 2025 and 2024 would have increased/decreased by \$8,815 thousand and \$6,559 thousand, respectively, as a result of the changes in fair values of financial assets at fair value through other comprehensive income.

4. Fair value information

1) The categories and fair values of financial instruments

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income is measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	December 31, 2025				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed shares	\$ 2,659	2,659	-	-	2,659
Foreign listed shares	248,855	248,855	-	-	248,855
Domestic unlisted shares	132,312	-	-	132,312	132,312
Foreign unlisted shares	497,648	-	-	497,648	497,648
Accounts receivable	3,581	-	-	-	-
Sub-total	<u>885,055</u>	<u>251,514</u>	<u>-</u>	<u>629,960</u>	<u>881,474</u>
Financial assets at amortized cost					
Cash and cash equivalents	2,847,128	-	-	-	-
Time deposits with original maturity of more than 3 months	612,160	-	-	-	-
Receivables	5,538,330	-	-	-	-
Guarantee deposits paid	282,019	-	-	-	-
Other financial assets	109,646	-	-	-	-
Sub-total	<u>9,389,283</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 10,274,338</u>	<u>251,514</u>	<u>-</u>	<u>629,960</u>	<u>881,474</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	December 31, 2025				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial liabilities at amortized cost					
Short-term and long-term borrowings	\$ 1,693,221	-	-	-	-
Payables	3,742,683	-	-	-	-
Guarantee deposits received	9,513	-	-	-	-
Lease liabilities	460,685	-	-	-	-
Total	<u>\$ 5,906,102</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
	December 31, 2024				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Derivative financial assets	\$ 117	-	117	-	117
Financial assets at fair value through other comprehensive income					
Domestic listed shares	2,391	2,391	-	-	2,391
Foreign listed shares	121,050	121,050	-	-	121,050
Domestic unlisted shares	151,165	-	-	151,165	151,165
Foreign unlisted shares	381,304	-	-	381,304	381,304
Sub-total	<u>655,910</u>	<u>123,441</u>	<u>-</u>	<u>532,469</u>	<u>655,910</u>
Financial assets at amortized cost					
Cash and cash equivalents	4,189,204	-	-	-	-
Time deposits with original maturity of more than 3 months	757,371	-	-	-	-
Receivables	5,890,325	-	-	-	-
Guarantee deposits paid	172,272	-	-	-	-
Other financial assets	138,748	-	-	-	-
Sub-total	<u>11,147,920</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 11,803,947</u>	<u>123,441</u>	<u>117</u>	<u>532,469</u>	<u>656,027</u>
Financial liabilities at amortized cost					
Short-term and long-term borrowings	\$ 917,531	-	-	-	-
Payables	6,286,239	-	-	-	-
Guarantee deposits received	11,148	-	-	-	-
Lease liabilities	506,170	-	-	-	-
Total	<u>\$ 7,721,088</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Valuation techniques for financial instruments not measured at fair value

The Group's valuation techniques and assumptions used for financial instruments not measured at fair value are as follows:

A. Financial assets measured at amortized cost

If the quoted prices in active markets are available, the market price is established as the fair value. However, if quoted prices in active markets are not available, the estimated valuation or prices used by competitors are adopted.

B. Financial liabilities measured at amortized cost

If there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimated fair values.

3) Valuation techniques for financial instruments measured at fair value

The Group considers the financial status, operating analysis, most recent transaction price, non-active market quoted price of related equity instrument, and active-market quoted price of similar instrument, and other information, in determining the input value of its investee companies. Periodically updates of information and input value for the valuation model and any necessary adjustments of fair value are required to ensure that the results of estimation are reasonable.

A. Non-derivative financial instruments

If quoted prices in active markets are available, the prices are established as fair values, such as public quoted company stock.

For the Group's financial instruments that have no active markets, the measurement of fair values is listed as follows:

Equity instrument that has no quoted price: The method of comparable Listed Company approach is used to estimate the fair value. The main assumption for the method is to determine the fair value by using the transaction price paid for an identical or a similar instrument of an investee.

B. Derivative financial instruments

Derivative financial instruments are measured by using the common valuation models such as discounted cash flow model and Black-Scholes model.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4) Changes in level 3 of the fair value

	Fair value through other comprehensive income
	unquoted equity instruments
Balance as of January 1, 2025	\$ 532,469
Total gains and losses recognized	
In other comprehensive income	97,976
Reclassification and effect of movements in exchange rates	(485)
Balance as of December 31, 2025	\$ 629,960
Balance as of January 1, 2024	\$ 594,570
Total gains and losses recognized	
In other comprehensive income	(62,285)
Reclassification and effect of movements in exchange rates	184
Balance as of December 31, 2024	\$ 532,469

For the years ended 2025 and 2024, the total gains and losses that were included in “unrealized gains and losses from financial assets at fair value through other comprehensive income” were as follows:

	For the Years Ended December 31,	
	2025	2024
Total gains and losses recognized		
In other comprehensive income, and presented in “unrealized gains and losses from financial assets at fair value through other comprehensive income”	\$ 97,976	(62,285)

5) Quantified information for significant unobservable inputs (level 3) used in fair value measurement

The Group’s financial instruments that use Level 3 inputs to measure fair value include “financial assets at fair value through other comprehensive income— equity investments without active market”.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation techniques	Significant non-observable inputs	The relationship between significant Non-observable inputs and fair value
Financial assets at fair value through other comprehensive income - equity instruments investments without an active market	Market approach- Company comparisons	<ul style="list-style-type: none"> · P/B Value Multiple (0.746~2.91 and 0.74~2.20 as of December 31, 2025 and December 31, 2024, respectively.) · Discount due to Lack of Market liquidity (12.93%~30% and 9.86%~30% as of December 31, 2025 and December 31, 2024, respectively.) 	· The estimated fair value would increase (decrease) if the value multiple is higher (lower) and the marketability discount is lower (higher)

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

6) Sensitivity analysis for fair values of financial instruments using Level 3 Inputs

The Group's fair value measurement on financial instruments is reasonable. However, the measurement would differ if different valuation models or valuation parameters are used. For financial instruments using level 3 inputs, if the valuation parameters are changed, the impact on net income or loss and other comprehensive income or loss will be as follows:

	Input	Variation	Impact on Fair Value Change on Other Comprehensive income or loss	
			Favorable Change	Unfavorable Change
December 31, 2025				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 30,654	(30,654)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	42,391	(42,391)
			\$ 73,045	(73,045)
December 31, 2024				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 26,139	(26,139)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	34,999	(34,999)
			\$ 61,138	(61,138)

(z) Financial risk management

1. Overview

The Group has exposures to the following risks from its financial instruments:

- 1) credit risk
- 2) liquidity risk
- 3) market risk

The following likewise discusses the Group's objectives, policies and processes for measuring and managing the above mentioned risks. For more disclosures about the quantitative effects of these risks exposures, please refer to the respective notes in the accompanying consolidated financial statements.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2. Risk management framework

The Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework. The general manager, which reports to the Board of Directors, is responsible for the development of the Group-Wide risk management policy and related systems and reports regularly to the Board of Directors.

The Group's risk management policies are established to identify and analyze the risks faced by the Group, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and changes in operation of the Group. The Group, through its training and management standards and procedures, aim to develop a disciplined and constructive control environment, in which all employees understand their roles and obligations.

The Group's Board of Directors oversees how management monitors compliance with the Group's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group's Board of Directors is assisted in its oversight role by internal audit. The internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the Board of Directors.

3. Credit risk

Credit risk refers to the risk that a counterparty would default on its contractual obligations resulting in financial loss to the Group. As at the end of the reporting period, the Group's maximum exposure to credit risk which will cause a financial loss to the Group due to failure of counterparties to discharge an obligation and financial guarantees provided by the Group could arise from:

- 1) The carrying amount of the respective recognized financial assets as stated in the consolidated balance sheets; and
- 2) The amount of contingent liabilities in relation to financial guarantee issued by the Group.

In order to minimize credit risk, the management of the Group has delegated a team responsible for determination of credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Group reviews the recoverable amount of each individual trade debt at the end of the reporting period to ensure that adequate impairment losses are made for irrecoverable amounts.

Please refer to Note (13)(a) for the information of guarantees and endorsements for subsidiaries as of December 31, 2025.

4. Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it always has sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

5. Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices, and credit spreads will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return on risk.

The Group buys and sells derivatives, and also incurs financial liabilities, in order to manage market risks. All such transactions are carried out within the guidelines set by the Board of Directors and shareholder's meeting with the supervision of the internal audit department. Information concerning all market risks of the Group was as follows:

1) Currency risk

The Group had foreign currency sales and purchases, which exposed the Group to foreign currency risk. Exchange rate exposures were managed within approved policy parameters utilizing forward foreign exchange contracts.

2) Interest rate risk

The Group was exposed to interest rate risk because entities in the Group borrowed funds at both fixed and floating interest rates. The Group pays attention to changes in market interest rates in order to make plans to manage interest rate risk.

3) Other price risk

The Group was exposed to price risk through its investments in listed securities. The Group has appointed a special team to monitor and evaluate the price risk.

(aa) Capital Management

The Group's objectives for managing capital to safeguard the capacity to continue to operate, to continue to provide a return on shareholders, to maintain the interest of other related parties, and to maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Group may adjust the dividend payment to the shareholders, reduce the capital for redistribution to shareholders, issue new shares, or sell assets to settle any liabilities.

The Group use the debt-to-equity ratio to manage capital. This ratio is the total net debt divided by the total capital. The net debt from the balance sheet is derived from the total liabilities less cash and cash equivalents. The total capital and equity include share capital, capital surplus, retained earnings, and other equity plus net debt.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(ab) Investing and financing activities not affecting current cash flow

The Group's investing and financing activities which did not affect the current cash flow in the years ended 2025 and 2024, were as follows:

For acquisitions of right-of-use assets by leasing, please refer to note 6(j).

Reconciliation of liabilities arising from financing activities were as follows:

	January 1, 2025	Cash flows	Non-cash changes			December 31, 2025
			Acquisition	Foreign exchange movement	Others	
Short-term and long-term borrowings	\$ 917,531	775,690	-	-	-	1,693,221
Lease liabilities	506,170	(137,284)	234,904	(1,553)	(141,552)	460,685
Total liabilities from financing activities	<u>\$ 1,423,701</u>	<u>638,406</u>	<u>234,904</u>	<u>(1,553)</u>	<u>(141,552)</u>	<u>2,153,906</u>

	January 1, 2024	Cash flows	Non-cash changes			December 31, 2024
			Acquisition	Foreign exchange movement	Others	
Short-term and long-term borrowings	\$ 1,134,887	(217,356)	-	-	-	917,531
Lease liabilities	306,795	(101,269)	428,840	175	(128,371)	506,170
Total liabilities from financing activities	<u>\$ 1,441,682</u>	<u>(318,625)</u>	<u>428,840</u>	<u>175</u>	<u>(128,371)</u>	<u>1,423,701</u>

(7) Related Party Transactions

(a) Names of related parties and their relationship with related parties

The followings are related parties that have had transactions with the Group during the periods covered in the consolidated financial statements.

<u>Name of related party</u>	<u>Relationship with the Group</u>
Excelsior Investment Co., Ltd.	Entities with significant influence over the Group
Excelsior Group Holdings Co., Ltd.	//
Xuan Hui Co., Ltd.	//
Bestchain Healthtaiwan Co., Ltd. (Bestchain)	Associate
Excelsior Renal Service Co., Limited (ERS)	//
Asia Best Healthcare Co., Limited (ABH)	//
Medifly Co., Ltd.	//
Asia Best Life Care Co., Ltd. (ABL)	//
Excelsior Long Term Care Corporation Entity	//
Medytox Taiwan Inc.	//
Touce Biotech Co., Ltd. (Touce Biotech)	//
Bestsmile Co., Ltd.(Bestsmile)	//

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

<u>Name of related party</u>	<u>Relationship with the Group</u>
Exceed Healthcare Co., Ltd.	Associate
Anxin Nice Care Co., Ltd.	//
NephroCare Limited	//
Cardinal Medical Services Ltd.	//
CYJ INTERNATIONAL COMPANY LIMITED (CYJ)	Associate (Note 1)
Excelsior Health Foundation	Other related parties

Note 1: CYJ INTERNATIONAL COMPANY LIMITED was dissolved by resolution of the shareholders' meeting on May 13, 2024.

(b) Significant transactions with related parties

1. Operating revenue

1) Sales revenue

The amounts of significant sales by the Group to related parties were as follows:

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Associate – Bestchain	\$ 2,465,339	2,471,348
Associate – ERS	765,882	775,076
Associate – Others	257,768	247,170
Other related parties	71	37
	<u>\$ 3,489,060</u>	<u>3,493,631</u>

The aforementioned transactions, except the sales to Bestchain and ERS that were priced on a cost-plus basis, were conducted on normal commercial terms.

2) Repair and maintenance revenue

The amounts of significant repair and maintenance revenue by the Group to related parties were as follows:

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Associate – ERS	\$ 93,155	98,139
Associate – Bestchain	12,450	8,940
Associate – Others	599	151
	<u>\$ 106,204</u>	<u>107,230</u>

There were no significant differences in the terms and pricing offered to related parties compared with those offered to third parties.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3) Other operating revenue-rental revenue

The amounts of significant other operating revenue-rental revenue by the Group to related parties were as follows:

	For the Years Ended December 31,	
	2025	2024
Entities with significant influence over the Group	\$ 72	72
Associate – ABH	34,614	16,868
Associate – ERS	4,521	4,280
Associate – ABL	4,487	9,123
Associate – Others	2,842	1,930
Other related parties	46	59
	<u>\$ 46,582</u>	<u>32,332</u>

The aforementioned transactions, except that the rental amounts were based on mutual agreements, all other terms were based on standard conditions.

4) Other operating revenue-service revenue

The amounts of significant other operating revenue-service revenue by the Group to related parties were as follows:

	For the Years Ended December 31,	
	2025	2024
Associate	\$ 12,168	16,361
Other related parties	312	250
	<u>\$ 12,480</u>	<u>16,611</u>

There were no significant differences in the terms and pricing offered to associates compared with those offered to third parties.

2. Purchases from related parties

The amounts of significant purchases by the Group from related parties were as follows:

	For the Years Ended December 31,	
	2025	2024
Associate	\$ 178,514	188,297

There were no significant differences in terms and conditions of the purchases from associates between those provided to the third parties.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3.Receivables from related parties

Receivables from related parties were as follows:

<u>Accounted for as</u>	<u>Category of related party</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Notes receivable	Associate	\$ 29	756
Other notes receivable	Associate	916	219
Accounts receivable	Associate—Bestchain	663,255	693,595
Accounts receivable	Associate—ERS	161,750	163,977
Accounts receivable	Associate—Others	55,001	47,620
Accounts receivable	Other related parties	62	5
Other receivables	Associate	2,097	5,715

4.Payables to related parties

Payables to related parties were as follows:

<u>Accounted for as</u>	<u>Category of related party</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Accounts payable	Associate	\$ 24,824	12,233
Other payables	Associate	16,053	11,657
Deposits received	Associate	7,891	7,713

5.Prepayments

Prepayments to related parties were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Associate	<u>\$ 10,967</u>	<u>28,293</u>

6.Property transactions

1) Purchases of property, plant and equipment

The purchases price of property, plant and equipment purchased from related parties are summarized as follows:

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Associate-Bestsmile	\$ 6,688	-
Associate—ERS	91	-
Associate—ABL	-	176
	<u>\$ 6,779</u>	<u>176</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Disposals of property, plant and equipment

The disposals of property, plant and equipment to related parties were summarized as follows:

<u>Category of related party</u>	<u>For the Years Ended December 31,</u>	
	<u>2024</u>	
	<u>Disposal price</u>	<u>Gains (losses) from disposal</u>
Associates	<u>\$ 88</u>	<u>40</u>

As of December 31, 2025, there were no such transactions.

3) Acquisitions of other assets

The acquisitions of other assets from related parties are summarized as follow:

<u>Relationship</u>	<u>Account</u>	<u>For the Years Ended December 31,</u>
		<u>2024</u>
Associates	Intangible assets	<u>\$ 1,480</u>

4) Disposals of financial assets

The disposals of financial assets to related parties are summarized as follows:

<u>Relationship</u>	<u>Account</u>	<u>2024</u>			<u>Gain (loss) on disposal</u>
		<u>Number of shares</u>	<u>Purpose</u>	<u>Disposal price</u>	
Associate – Bestchain	Investments accounted for using equity method	1,500,000	Ordinary shares of Dynamic	<u>\$ 159,043</u>	<u>-</u>

As of December 31, 2025, there were no such transactions.

7. Guarantee

As of December 31, 2025 and 2024, the Group provided associates guarantees for loans. The credit limit of the guarantees were \$1,200,000 thousand, \$1,200,000 thousand, and the amount utilized were \$200,000 thousand, and \$285,000 thousand, respectively.

8. Capital and Equity

For future planning purposes, the Group increased its investment in Associates - Medytox Taiwan Inc. by NT\$8,000 thousand in 2025, with no change in its ownership percentage after the capital injection.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

9. Others

	For the Years Ended December 31,	
	2025	2024
<u>Associates and Other related parties</u>		
Other revenue	\$ 2,317	2,903
Cost of goods sold	(9,490)	(8,568)
Repair and maintenance costs	(7,363)	(7,697)
Fright and warehousing expense	(52,675)	(49,514)
Rent expense	(4,148)	(4,503)
Other expense	(30,632)	(26,260)

The aforementioned rentals collected or paid quarterly or monthly were based on prevailing market rates.

As of December 31, 2025 and 2024, the Group had received collections in advance from associates for \$1,292 thousand and \$3,339 thousand, respectively.

(c) Key management personnel compensation

Key management personnel compensation comprised:

	For the Years Ended December 31,	
	2025	2024
Short-term employee benefits	\$ 81,078	88,130
Post-employment benefit	1,092	1,399
	\$ 82,170	89,529

(8) Pledged Assets

The carrying amount of pledged assets were as follows:

Pledged assets	Object	December 31, 2025	December 31, 2024
Current deposits and time deposits	Bank loans, bank guarantee and credit card document receiving service guarantee	\$ 109,646	136,537
Notes receivable and other notes receivable	Guarantee of short-term loan or strengthening credit	197,298	213,352
Property, plant and equipment	Bank loans	99,403	94,351
Investment property	"	1,346,530	1,497,473
Refundable deposits (Recognized in other non-current financial assets)	Guarantees for sales performance, deposits and lease deposits, etc.	282,019	170,199
		\$ 2,034,896	2,111,912

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(9) Significant Commitments and Contingencies

(a) Unrecognized contractual commitments

1. As of December 31, 2025 and 2024, the unused letters of credit were \$54,634 thousand and \$28,792 thousand, respectively. The guarantee letters issued by banks for sales contract guarantee and purchase bid of hospital were \$1,054,975 thousand and \$932,010 thousand, respectively.
2. In April 2022, the Company entered into a supply agreement with the Hong Kong-based company. Pursuant to the agreement, the Company shall purchase certain products from the Hong Kong-based company in agreed quantities at agreed prices annually.
3. The Group won the bid for the procurement project for COVID-19 treatment drugs (including storage and distribution) from the Centers for Disease Control, Ministry of Health and Welfare (CDC), who entered into an agreement with the Group on July 17, 2024, in which the Group will purchase drugs and provide storage and distribution services to the CDC.
4. As of December 31, 2025 and 2024, due to the acquisition of the hospital procurement project by the Group, the amounts of the performance guarantee letters issued by the bank were NT\$1,002,795 thousand and NT\$921,010 thousand, respectively.
5. On November 7, 2025, the Board of Directors approved the plan to enter into a warehouse lease agreement with its related party, Bestchain Healthtaiwan Co., Ltd., in consideration of future operational requirements and business development. The total contract amount is NT\$99,500 thousand.

(10) Losses due to Major Disasters : None.

(11) Subsequent Events

On November 7, 2025, the Board of Directors passed a resolution to issue 16,800 (in thousands) shares of common stock for the capital increase in cash, including 2,520 (in thousands) shares subscribed by employees and 1,680 (in thousands) shares for public offerings, at an issue price of \$ 60 per share. This capital increase was reported by the competent authority and took effect on December 22, 2025. The total cash subscription proceeds of \$1,008,000 (in thousands) have been received in full. The base date of the capital increase is January 29, 2026.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(12) Other

- (a) The employee benefits, depreciation, depletion and amortization expenses categorized by function were as follows:

By item	By function	For the Years Ended December 31, 2025			For the Years Ended December 31, 2024		
		Operating cost	Operating expense	Total	Operating cost	Operating expense	Total
Employee benefits							
Salary		308,863	518,620	827,483	291,493	447,400	738,893
Labor and health insurance		29,851	44,290	74,141	27,120	39,589	66,709
Pension		14,713	22,897	37,610	13,970	23,282	37,252
Others		15,231	26,439	41,670	14,055	23,357	37,412
Depreciation		223,567	82,483	306,050	238,173	56,803	294,976
Amortization		622	7,011	7,633	1,384	4,472	5,856

(13) Other disclosures

- (a) Information on significant transactions

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Group for the year ended December 31, 2025:

1. Fund financing to other parties: None.
2. Guarantees and endorsements for other parties:

(Expressed in thousands of New Taiwan dollars)

No.	Endorsement/guarantee provider	Counter-party		Limitation on endorsement/guarantee amount provided to each guaranteed party	Maximum balance for the year	Ending balance	Amount actually drawn	Amount of endorsement/guarantee collateralized by properties	Ratio of accumulated endorsement/guarantee to net equity per latest financial statements	Maximum endorsement guarantee amount allowance (Note 7)	Guarantee provided by parent company	Guarantee provided by a subsidiary	Guarantee provided to subsidiaries in Mainland China
		Name	Nature of relationship (Note 2)										
0	The Company	Excelsior Asset Management CO., Ltd. (Note 4)	2	1,838,457	990,000	570,000	-	-	6.20 %	9,192,287	Y	N	N
0	"	EG Healthcare, Inc. (Note 4)	2	1,838,457	146,450	120,965	-	-	1.32 %	9,192,287	Y	N	N
0	"	Renal Laboratories Sdn. Bhd. (Note 4)	2	1,838,457	83,013	78,575	11,221	-	0.85 %	9,192,287	Y	N	N
0	"	Medi-Chem System Sdn. Bhd. (Note 4)	2	1,838,457	16,603	15,715	-	-	0.17 %	9,192,287	Y	N	N
0	"	Excelsior Renal Service Co., Limited (Note 3)	1	765,524	-	-	-	-	- %	9,192,287	N	N	N
0	"	Bestchain Healthtaiwan Co., Ltd. (Note 3)	1	2,464,263	1,200,000	1,200,000	200,000	-	13.05 %	9,192,287	N	N	N
1	Dynamic Medical Technologies Inc.	CYJ International Taiwan Inc. (Note 5)	2	333,731	200,000	100,000	-	-	5.99 %	834,327	Y	N	N

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

No.	Endorsement/guarantee provider	Counter-party		Limitation on endorsement/guarantee amount provided to each guaranteed party	Maximum balance for the year	Ending balance	Amount actually drawn	Amount of endorsement/guarantee collateralized by properties	Ratio of accumulated endorsement/guarantee to net equity per latest financial statements	Maximum endorsement/guarantee allowance (Note 7)	Guarantee provided by parent company	Guarantee provided by a subsidiary	Guarantee provided to subsidiaries in Mainland China
		Name	Nature of relationship (Note 2)										
2	Arich Best Chain Co., Ltd.	Arich Enterprise Co., Ltd. (Note 6)	3	9,432	-	-	-	-	%	15,721	N	Y	N

Note 1: the description of number column:

1. 0 is issuer.
2. Investees are listed by name and numbered starting with 1.

Note 2: Relationship with the Company

1. The companies with which it has business relations.
2. Subsidiaries in which the Company directly or indirectly holds more than 50% of its total outstanding common shares.
3. The parent company which directly or indirectly holds more than 50% of its voting rights.
4. Subsidiaries in which the Company directly or indirectly holds more than 90% of its voting rights.
5. Companies in the same type of business and providing mutual endorsements/ guarantees in favor of each other in accordance with the contractual obligations in order to fulfill the needs of the construction project.
6. Shareholders making endorsements and/or guarantees for their mutually invested company in proportion to their shareholding percentage.
7. Companies in the same type of business providing guarantees of pre-sale contracts according to the regulation.

Note 3: For guarantee and endorsement to those companies with business contact, the maximum amount cannot exceed the trading amount between two parties for the current year.

Note 4: The total amount of guarantee and endorsement cannot exceed 20% of the Company's net asset value from the most recent audited or reviewed report.

Note 5: The total amount of guarantee and endorsement cannot exceed 20% of Dynamic's net asset value from the most recent audited or reviewed report.

Note 6: The total amount of guarantee and endorsement cannot exceed 30% of Arich Best Chain's net asset value from the most recent audited or reviewed report.

Note 7: The total amount of guarantee and endorsement cannot exceed the Company's net asset value from the most recent audited or review report: Dynamic and Arich Best Chain cannot exceed 50% of its net asset value from the most recent audited or reviewed report.

3. Information regarding securities held at balance sheet date (excluding investment in subsidiaries, associates and joint ventures):

(Expressed in thousands of New Taiwan dollars)

Name of holder	Category and name of security	Relationship with the Company	Account title	Ending balance				Peak Holding Percentage	Notes
				Number of shares	Book value	Percentage of shares	Market value		
The Company	3-D Matrix, Ltd.	-	Fair value through other comprehensive income	273,400	19,709	0.23 %	19,709	0.23 %	
"	Gie Cheng Co., Ltd.	-	"	3,795,000	32,333	17.25 %	32,333	17.25 %	
"	Rui Guang Healthcare Co., Ltd.	-	"	2,423,951	31,851	7.15 %	31,851	7.15 %	
"	Sunder Biomedical Tech. Co., Ltd.	-	"	2,279,578	50,037	3.80 %	50,037	3.80 %	
"	Linkon International Golf & Country Club	-	"	1	15,350	0.10 %	15,350	0.10 %	
"	Chi Sheng Pharma & Biotech Co., Ltd.	-	"	90,300	2,659	0.15 %	2,659	0.15 %	
Excelsior Healthcare Co. Limited	Chai Tai Bo Ai Investment Limited	-	"	10,000	-	8.00 %	-	-	
EG Healthcare, Inc.	The Orchard Golf & Country Club	-	"	1	2,084	- %	2,084	- %	
Dynamic Medical Technologies Inc.	Caregen Co., Ltd.	-	"	145,000	229,146	0.27 %	229,146	0.32 %	
Excelsior Beauty Co., Ltd.	Join Fun Co., Ltd.	-	"	263,340	2,741	19.00 %	2,741		
Arich Enterprise Co., Ltd.	National Pharmaceutical Logistics Corp., Ltd.	Board director of investee	"	-	495,564	17.65 %	495,564	17.65 %	Note

Note : Act as limited company, no outstanding share.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4. Buying/selling products with the amount reaches \$100 million or 20% or more of paid-in capital:

(Expressed in thousands of New Taiwan dollars)

Name of company	Name of Counter-party	Relationship	Transaction details				Transactions with terms different from others		Account/note receivable (payable)		Notes
			Purchase/Sale	Amount	Percentage of total purchases/sales	Credit period	Unit price	Credit period	Balance	Percentage of total accounts/notes receivable (payable)	
The Company	Excelsior Renal Service Co., Limited	Associates	Sales	765,524	(14.10)%	Net 30-60 days	-	-	161,750	12.09 %	Note 1
"	Bestchain Healthtaiwan Co., Ltd.	"	"	2,464,263	(45.39)%	Net 30-90 days	-	-	662,968	49.53 %	Note 1
"	NEPHROCARE LIMITED, TAIWAN BRANCH	"	"	125,630	(2.31)%	Net 45 days	-	-	23,670	1.77 %	Note 1
Dynamic Medical Technologies Inc.	CYJ International Taiwan Inc.	Subsidiary	Sales	100,287	(12.85)%	Net 150 days	-	-	63,373	36.64 %	Note 1
"	Medytox Taiwan Inc.	Associates	Purchases	88,836	21.35 %	Net 30 days	-	-	14,368	29.78 %	Note 2

Note 1: The unit price of cost of goods sold for the Company is based on cost-plus pricing approach by product that is lower than average; because, the expense of goods sold for related parties is lower than average price as well.

Note 2: The company's sales are the same as those for general transactions.

Note 3: The purchase price and payment terms are not significantly different from other purchase objects.

5. Accounts receivable from related parties for which the amount reaches \$100 million or 20% or more of paid-in capital:

(Expressed in thousands of New Taiwan dollars)

Name of related party	Counter-party	Relationship	Balance of receivables from related party	Turnover rate	Past-due receivables from related party		Subsequently received amount of receivables from related party	Allowances for bad debts
					Amount	Action taken		
The Company	Excelsior Renal Service Co., Limited	Associates	161,750	4.70	-	-	154,085	-
"	Bestchain Healthtaiwan Co., Ltd.	"	662,968	3.63	-	-	223,751	-

6. Business relationships and significant inter-company transactions:

Number	Name of the company	Name of the counter-party	Existing relationship with the counter-party	Transaction details during 2025			Percentage of the total consolidated revenue or total assets
				Account name	Amount	Terms of trading	
0	The Company	EG Healthcare, Inc.	1	Sales	138,850	Usual terms and conditions	1.58 %
"	"	"	1	Account Receivable	72,216	The same as the term for other general trading partners	0.38 %
1	Dynamic Medical Technologies Inc.	CYJ International Taiwan Inc.	3	Account Receivable	63,373	The same as the term for other general trading partners	0.33 %
"	"	"	3	Sales	106,936	The same as the term for other general trading partners	1.22 %

Note 1: The numbers denote the following:

1. 0 represents the Company.
2. Subsidiaries are listed by names and numbered starting with 1.

Note 2: Relationship with the listed companies:

1. The Company to subsidiary
2. Subsidiary to the Company
3. Subsidiary to subsidiary

Note 3: The transaction amount is calculated as a proportion of the consolidated revenue or assets. If categorized as an asset or liability, the calculation is compared with the consolidated assets; if categorized as income or loss, the calculation is compared with the consolidated income or loss.

Note 4: The aforementioned inter-company transactions have been eliminated in the consolidated financial statements.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(b) Information on investees:

For the year ended December 31, 2025, the following is the information of investees (excluding investees in Mainland china):

(Amounts Expressed in Thousands of New Taiwan Dollars, Except for Share Data)

Name of the investor	Name of investee	Location	Major operations	Initial investment amount		Ending balance			Peak Holding Percentage	Net income (loss) of the investee	Investment income (losses)	Notes
				Ending balance	Beginning balance	Shares	Ratio of shares	Book value				
The Company	Bestchain Healthtaiwan Co., Ltd.	New Taipei City	Sale of medical equipment and medicines, interagation of warehousing and information	299,024	299,024	55,235,590	44.71 %	1,123,748	44.71 %	224,823	100,437	Associates (Note 1)
"	Arich Enterprise Co., Ltd.	New Taipei City	Sale of medicines, and logistics service	380,856	380,856	29,829,742	40.00 %	802,431	40.00 %	86,792	34,714	Subsidiary (Note 2)
"	Dynamic Medical Technologies Inc.	New Taipei City	Sale, maintenance and lease of laser medical equipment for beauty treatment, and sale of consumables of beauty treatment and cosmetic products	116,131	116,113	13,563,450	33.97 %	577,840	33.97 %	152,060	51,610	Subsidiary
"	Excelsior Healthcare Co., Limited	British Virgin Islands	Investment business	898,782	898,782	28,695,856	100.00 %	1,818,951	100.00 %	193,472	193,472	Subsidiary
"	Sunrise Health Care Company	New Taipei City	Sale of medical equipment, and medical management consultancy service	18,806	18,806	2,085,547	20.86 %	28,125	20.86 %	704	157	Associates
"	Excelsior Medical (HK) Co., Limited	Hong Kong	Investment business	963,137	963,137	33,807,013	64.36 %	1,284,112	64.36 %	155,181	99,874	Subsidiary
"	Excelsior Beauty Co., Ltd.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	28,543	28,543	5,190,662	41.02 %	92,813	41.02 %	44,296	18,174	Sub-subsubsidiary
"	Excelsior Asset Management Co., Ltd.	New Taipei City	Sales of medical equipment, precision instrument and real estate	780,525	780,525	87,375,600	100.00 %	717,317	100.00 %	37,970	37,970	Subsidiary
"	Medifly Co., Ltd.	Taichung	Sale of medical equipment and medicines	31,899	31,899	3,615,976	28.66 %	101,288	28.66 %	33,710	9,661	Associates
"	Asia Best Life Care Co., Ltd	New Taipei City	Long-term care business	953,836	953,836	84,633,340	49.02 %	1,035,423	49.38 %	140,361	69,188	Associates
Excelsior Healthcare Co., Limited	EG Healthcare, Inc.	Philippines	Sale and lease of medical equipment, and medical management consultancy service	19,256	19,256	9,427,489	99.99 %	154,625	99.99 %	65,011	-	Sub-subsubsidiary
"	Excelsior Renal Service Co., Limited	Hong Kong	Sale, maintenance and lease of medical equipment, and medical management consultancy service	312,505	312,505	73,375,728	49.00 %	402,845	49.00 %	165,642	-	Associates

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of the investor	Name of investee	Location	Major operations	Initial investment amount		Ending balance			Peak Holding Percentage	Net income (loss) of the investee	Investment income (losses)	Notes
				Ending balance	Beginning balance	Shares	Ratio of shares	Book value				
Excelsior Healthcare Co., Limited	Excelsior Medical (HK) Co., Limited	Hong Kong	Investment business	516,071	516,071	18,724,062	35.64 %	711,090	35.64 %	155,581	-	Subsidiary
"	Excelsior Investment (Malaysia) Co., Ltd	British Virgin Islands	Investment business	343,026	343,026	11,171,272	100.00 %	322,296	100.00 %	(12,292)	-	Sub-subsidiary
Dynamic Medical Technologies Inc.	Dynamic Medical Technologies (Hong Kong) Ltd.	Hong Kong	Sale of cosmetic health-care products	104,652	382,278	13,061,783	100.00 %	58,843	100.00 %	1,938	-	Sub-subsidiary (Note 4)
"	Excelsior Beauty Co., Ltd.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	55,395	55,395	6,819,523	53.89 %	115,226	53.89 %	44,296	-	Sub-subsidiary (Note 1)
"	Medytox Taiwan Inc.	New Taipei City	Sale of cosmetic health-care products	26,000	18,000	2,600,000	40.00 %	5,351	40.00 %	4,722	-	Associates (Note 5)
"	TOUCE BIOTECH Co., Ltd	Taipei City	Sale of cosmetic health-care products	45,000	45,000	420,000	35.00 %	45,267	35.00 %	6,212	-	Associates
"	CYJ International Taiwan Inc.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	155,709	155,709	13,851,588	55.41 %	142,959	55.41 %	16,348	-	Sub-subsidiary
Arich Enterprise Co., Ltd.	Arich Best Chain Co., Ltd.	New Taipei City	Logistics Business	31,080	31,080	3,000,000	100.00 %	32,201	100.00 %	1,119	-	Sub-subsidiary
Excelsior Medical (HK) Co., Limited	Asia Best Healthcare Co., Ltd.	Cayman Islands	Long-term care business	458,902	458,902	129,492	48.47 %	618,784	48.47 %	83,110	-	Associates
"	Cardinal Medical Services Ltd.	British Virgin Islands	Sale of medical equipment, and medical management consultancy service	106,121	106,121	9,800	49.00 %	123,026	49.00 %	76,425	-	Associates
"	NephroCare Limited	Hong Kong	Sale of medical equipment, and medical management consultancy service	688,755	688,755	151,801,588	49.00 %	733,559	49.00 %	131,675	-	Associates
Excelsior Investment (Malaysia) Co., Ltd	Renal Laboratories Sdn. Bhd.	Malaysia	Manufacture of medical equipment	288,387	288,387	32,523,586	81.90 %	276,023	81.90 %	(14,415)	-	Sub-subsidiary
"	Medi-Chem Systems Sdn. Bhd.	Malaysia	Sale of medical equipment	44,052	44,052	350,000	70.00 %	40,955	70.00 %	2,096	-	Sub-subsidiary
Medi-Chem Systems Sdn. Bhd.	Renal Management Sdn. Bhd.	Malaysia	Lease business	1,315	1,315	200,000	100.00 %	9,561	100.00 %	51	-	Sub-subsidiary

Note 1: Including the adjustment made from the unrealized gain/loss with subsidiaries and associates.

Note 2: Including the amortization listed by the book value of net identified assets.

Note 3: According to the regulations, the Company are required to disclose the share of income/loss of investees.

Note 4: Dynamic Medical Technologies (Hong Kong) Limited., resolved by its Board of Directors to conduct a cash capital reduction by reducing its cash capital of HKD65,960 thousand, with the paid-in capital of HKD 13,062 thousand after the reduction. The related capital reduction registration procedures had been completed with the competent authority on February 24, 2025.

Note 5: On August 28, 2025, the Board of Directors of Medytox Taiwan Inc. approved a cash capital increase of \$20,000 (in thousands), and set October 23, 2025, as the record date for the issuance of new shares. Following the capital increase, the number of issued shares increased to 6,500 thousand shares of common stock. The amendment registration has been completed with the Administration of Commerce, Ministry of Economic Affairs.

Note 6: The aforementioned inter-company transactions have been eliminated in the consolidated financial statements.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(c) Information on investment in Mainland China:

1. Information on investment in Mainland China:

(Amounts Expressed in Thousands of New Taiwan Dollars)

Name of the investee	Main Businesses and products	Total amount of pain-in capital	Method of investment (Note 1)	Accumulated outflow of investment from Taiwan as of January 1, 2025	Investment flows		Accumulated outflow of investment from Taiwan as of June 30, 2025	Net income (loss) of the investee	Direct /indirect shareholding (%) by the Company	Peak Holding Percentage	Current investment gains and losses	Carrying Amount	Accumulated Inward Remittance of Earnings
					Out-flow	Inflow							
Excelsior Healthcare (Shanghai) Corporation (Note 3)	Sale and lease of medical equipment, and medical management consultancy service	-	(2)	30,240	-	-	30,240	-	- %	- %	-	-	-
Shanghai Lintech Medicare Co. (Note 4)	Sale and maintenance of medical equipment	-	(2)	29,213	-	-	29,213	-	- %	- %	-	-	-
Pacific Beijing Bo-Ai Medical Management Consulting Co., Ltd.	Investment business and medical management consultancy service	84,187	(2)	80,327	-	-	80,327	(193)	7.80 %	7.80 %	-	-	-
SinoExcelsior Investment Inc. (Note 5, 7)	Sale of medical equipment, and medical management consultancy service	179,004	(2)	947,845	-	-	947,845	47	100.00 %	100.00 %	47	30,326	-
Guangzhou Dynamic Inc.	Sale and maintenance of medical equipment	44,346	(2)	119,574	-	-	119,574	(1,083)	100.00 %	100.00 %	(1,083)	7,111	-
Beijing Dynamic Inc. (Note 6)	Sale and maintenance of medical equipment	-	(2)	34,424	-	27,323	7,101	-	- %	- %	-	-	-
National Pharmaceutical Logistics Corp., Ltd.	Medical logistics	370,493	(3)	66,603	-	-	66,603	61,425	17.65 %	17.65 %	-	495,564	93,846

2. Limitation on investment in Mainland China:

Company	Accumulated Investment in Mainland China as of December 31, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment (Note 8)
The Company	1,087,625	1,289,640	5,515,361
Dynamic Medical Technologies Inc.	126,675	126,675	1,001,030
Arich Enterprise Co., Ltd.	66,603	66,603	1,206,837

Note 1: Investments in Mainland China are differentiated by the following four methods:

- (1) Direct investment in Mainland China with remittance through a third region.
- (2) Indirect investment in Mainland China through an existing investee company in a third region.
- (3) Other methods (i.e. entrusted Investment)

Note 2: Recognition of investment gain or loss during current period is pursuant to the following:

- (1) If the corporation is in the set-up phase, notes are required.
- (2) Recognition basis of investment gains or losses is determined by the following three types, and related notes are required.
 - 1) Financial statements of the investee company were audited and certified by an international firm in cooperation with an R.O.C. accounting firm.
 - 2) Financial statements of the investee company were audited and certified by the external accountant of the parent company.
 - 3) Others

Note 3: The liquidation procedure of Excelsior Healthcare (Shanghai) Corporation was completed in March 2016, and the investment had remitted to Excelsior Healthcare Co., Limited in the third place. As of December 31, 2025, the accumulated amount of investment from Taiwan has not been repatriated yet.

Note 4: The disposal of Shanghai Lintech Medicare Co. was completed in December 2015. As of December 31, 2025, the original investment amount of \$29,213 thousand from Taiwan has not been repatriated yet.

Note 5: The current investment outflow is not included the direct investment amount of \$207,380 thousand through the third region.

Note 6: The liquidation, with the deductible amount of USD 826 thousand, had been completed in November 2018, and the Investment Commission's authorization letter was obtained on April 10, 2025.

Note 7: Based on a resolution approved during its board meeting held on December 18, 2024, Sino Excelsior Investment Inc. conducted a cash capital reduction of CNY25,000 thousand, at a ratio of 42% with the approval of the competent authority on February 6, 2025. The fund had been remitted to Excelsior Medical (HK) Co., Ltd., belonging to a third region. As of December 31, 2025, the accumulated amount of investment from Taiwan has not yet to be repatriated.

Note 8: (1)The upper limit on investment of the Company and Dynamic is the 60% of net value.

(2)The upper limit on investment of Arich is the higher of \$80,000 thousand or 60% of net value.

Note 9: All amounts listed are disclosed in NTD.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3. Significant transactions :

The significant inter-company transactions with the subsidiary in Mainland China, which were eliminated in the preparation of consolidated financial statements, are disclosed in “Information of significant transactions”.

(14) Segment Information

(a) General information

Information reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the types of company. Specifically, the Group’s reportable segments were as follows:

1. Excelsior segment - the Company.
2. Dynamic segment - Dynamic, Hong Kong Dynamic, Excelsior Beauty, Guangzhou Dynamic, and CYJ International Taiwan Inc..
3. Arich segment - Arich.
4. Other segment - Bestsmile, Excelsior Healthcare, EG Healthcare, Excelsior Investment (Malaysia), RENAL LABORATORIES SDN. BHD., MEDI-CHEM SYSTEMS SDN. BHD., RENAL MANAGEMENT SDN. BHD., Excelsior Asset, Hong Kong Excelsior and SinoExcelsior Investment.

(b) Information about reportable segments and their measurement and reconciliations

The Group uses the internal management report that the chief operating decision maker reviews as the basis to determine resource allocation and make a performance evaluation. The internal management report includes profit before taxation, but not including any extraordinary activity and foreign exchange gain or losses because taxation, extraordinary activity, and foreign exchange gain or losses are managed on a group basis, and hence they are not able to be allocated to each reportable segment. In addition, not all reportable segments include depreciation and amortization of significant non-cash items. The reportable amount is similar to that in the report used by the chief operating decision maker.

The operating segment accounting policies are similar to those described in Note (4) “significant accounting policies” except for the recognition and measurement of pension cost, which is on a cash basis.

The Group’s operating segment information and reconciliation are as follows:

<u>For the Years Ended December 31, 2025</u>	<u>Excelsior segment</u>	<u>Dynamic segment</u>	<u>Arich segment</u>	<u>Others</u>	<u>Adjustment and Elimination</u>	<u>Total</u>
Revenue						
Revenue from external customers	\$ 5,269,443	1,383,391	1,546,999	589,403	-	8,789,236
Inter-segment revenue	159,987	3,369	-	44,852	(208,208)	-
Interest revenue	2,446	39,095	10,066	26,751	(2,777)	75,581
Total	\$ 5,431,876	1,425,855	1,557,065	661,006	(210,985)	8,864,817
Interest expense	\$ 5,152	4,816	7,531	17,946	(527)	34,918
Depreciation and amortization	53,027	149,505	67,422	48,332	(4,603)	313,683
Reportable segment profit (loss)	\$ 930,016	217,822	109,210	360,708	(435,849)	1,181,907

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

<u>For the Years Ended December 31, 2024</u>	<u>Excelsior segment</u>	<u>Dynamic segment</u>	<u>Arich segment</u>	<u>Others</u>	<u>Adjustment and Elimination</u>	<u>Total</u>
Revenue						
Revenue from external customers	\$ 5,200,483	1,569,552	1,297,743	470,768	-	8,538,546
Inter-segment revenue	90,497	3,152	24	75,692	(169,365)	-
Interest revenue	2,760	33,973	10,491	30,349	(837)	76,736
Total	\$ 5,293,740	1,606,677	1,308,258	576,809	(170,202)	8,615,282
Interest expense	\$ 5,562	5,468	6,342	10,276	(532)	27,116
Depreciation and amortization	43,157	177,776	41,981	39,476	(1,558)	300,832
Reportable segment profit (loss)	\$ 887,714	289,666	115,834	220,840	(339,692)	1,174,362

(c) Product and service information

Revenue from the external customers of the Group, please refer to Note 6(v).

(d) Geographical information

<u>By region</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Non-current assets:		
Taiwan	\$ 2,371,174	2,511,392
Hong Kong	292	1,526
China	5	12
Philippines	76,074	55,540
Malaysia	237,483	225,311
Total	\$ 2,685,028	2,793,781

Non-current assets include property, plant and equipment, right-of-use assets, investment properties, intangible assets, and other assets, but do not include financial instruments, deferred tax assets, pension assets, and rights from insurance contracts.

(e) Revenue from main customers

	<u>For the Years Ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Bestchain	\$ 2,480,965	2,482,312
Excelsior Renal Service	872,124	885,991
	\$ 3,353,089	3,368,303